JPS6147500A - キメラモノクロ−ナル抗体及びその製造法 - Google Patents

キメラモノクロ−ナル抗体及びその製造法

Info

Publication number
JPS6147500A
JPS6147500A JP16937084A JP16937084A JPS6147500A JP S6147500 A JPS6147500 A JP S6147500A JP 16937084 A JP16937084 A JP 16937084A JP 16937084 A JP16937084 A JP 16937084A JP S6147500 A JPS6147500 A JP S6147500A
Authority
JP
Japan
Prior art keywords
human
cells
monoclonal antibody
chimeric monoclonal
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP16937084A
Other languages
English (en)
Other versions
JPH0373280B2 (ja
Inventor
Katsu Taniguchi
克 谷口
Yoshikazu Kurosawa
黒沢　良和
Kozo Sugita
杉田　幸三
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Japan Science and Technology Agency
Original Assignee
Research Development Corp of Japan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15885326&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JPS6147500(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Research Development Corp of Japan filed Critical Research Development Corp of Japan
Priority to JP16937084A priority Critical patent/JPS6147500A/ja
Priority to DE19853587360 priority patent/DE3587360T2/de
Priority to EP85102665A priority patent/EP0171496B1/en
Priority to DE1985102665 priority patent/DE171496T1/de
Priority to CA 476731 priority patent/CA1339201C/en
Publication of JPS6147500A publication Critical patent/JPS6147500A/ja
Publication of JPH0373280B2 publication Critical patent/JPH0373280B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

(57)【要約】本公報は電子出願前の出願データであるた
め要約のデータは記録されません。

Description

【発明の詳細な説明】 ・本発明はキメラモノクローナル抗体及びその製造法に
関し、特に人体に投与した場合にアナフィラキシ−ショ
ックや血清病などの副作用の少ないモノクローナル抗体
及びその製造法に関する。
単−抗原決定基だけを認識するモノクローナル抗体は免
疫学全体に大きな影響を与え、その有用性は医学界にと
ソまらず生物学、薬学、化学などの多くの分野で証明さ
れている。そして、このモノクローナル抗体を得る方法
に関しては１９７５年に゛６旧ｅｒとＭｉｌｓｔｅｉユ
がヒツジ赤血球で免疫したマウスの牌細胞とマウスミエ
ローマ細胞と全細胞融合させることで実現しく　Ｎａｔ
ｕｒｅ２５６４９５−４９７（１９７５））、この外エ
プスタイン−／ぐ一ル（Ｅｐｓｔｅｉｎ−Ｂａｒｒ）ウ
ィルスにヨル方法ナトカする（特開昭５８−２０１’７
２３号参照）。しかして、これらのモノクローナル抗体
の多くけそれ自体がマウス等人間以外の動物に由来する
ためそれを人間に投与した場合には異種蛋白を注射する
ことになり、その結果、アナフィラキシ−ショックや血
清病などの副作用がおこることが予想される。そのため
、ヒトハイブリドーマを用いてヒトモノクローナル抗体
を作成する試みがなされている。
（例えば特願昭５７−１２６４２４、特願昭５７−５０
２０９０、特願昭５８−９０５１７、特願昭部” ８’、　−、、］、　２８３２３及び特願昭５７−５０
２０９号参照）これらによればヒト型のモノクローナル
抗体を得ることは可能であるが必ずしも再現性等の点に
おいて満足すべきものとは云えない。（Ｎａ−ｔｕｒｅ
３００３　：＋、　６〜３１７（１９８２）参照）また
、マウス等の動物は容易ＶＣ種々の抗原で免疫すること
は可能であるが人間については望む抗原を用いて自由に
免疫できないという欠点がある。
一方、ヒト型モノクローナル抗体を産生ずるヒトＸマウ
スハイブリＶ−マを作製してμ鎖特異的ｍＲＮＡを得た
のち相補鎖ＤＮＡを作製し、プラスミドｐＢＲ３２２に
組み込んで大腸菌にヒトモノクローナル片体全生産させ
る試みを行っているがこの方法も人間には自由に免疫で
きないという点で問題が残る。
本発明者はこれらの欠点全改善すべり枝々の研究全行い
本発明を完成するに至ったのである。すなわち本発明は
ヒト以外の動物由来の可変領域とヒト由来の定常領域か
らなるキメラモノクローナル抗体であって、とれの製造
方法はヒト以外の動１の抗体産生細胞から単離した活性
なりＨとＶＬ遺伝子及びヒトＤＮＡから単離した鮨とＯ
Ｌ遺伝子を発現ベクター例挿入し動物培養細胞に導入し
てキメラモノクローナル抗体を産生させることからなる
。ここで活性な■ゆと■１遺伝子　とは抗体産生細胞に
おいてＤＮＡの再配列によって出来たＶＨにちってはＶ
−ｒ）−Ｊ、ＶＬＫちうてはＶ−Ｊ構造を有する機能的
な遺伝子でちる。しかして１本発明においてヒト以外の
動物としてはマウス、ラット、サル、羊、ウサギ等であ
り、また、抗体産生細胞としては好ましくけハイプリ　
Ｐ　−マ、クローン化Ｂ細胞或はエプスタインパールウ
ィルスによる形質転換Ｂ細胞を用いることが望ましく１
発現ベクターとしてはｐｓ’Ｖ２−ｇｐｔ、ｐＳＶ２−
ｎｅｏ　、　ＳＶ４０が好適でちる。動物培養細胞には
、ヒト、サル、マウス等の動物に由来するリンノミ腫、
腎細胞、Ｌ細胞、　Ｏｏ８細胞、ＨｅＬａ細胞の何れか
を用いることができる゛しかして１本発明に従えばヒト
以外の動物は自由に免疫できるので容易に所望のキメラ
モノクローナル抗体を得ることができると共に１人間に
投与した場合動物由来のモノクローナル抗体に比して異
種蛋白による抗原性が著しく軽減されることが期待され
る。
次に実施例をもって本発明を説明する。
実施例 マウスＶ遺伝子の単離 腫瘍細胞Ｐ３Ｕ１と０５７８Ｌ／６マウスに自然発生し
た黒色腫瘍細胞で免疫し；ｇ　０５７ＢＬ／６マウスに
由来する肺臓細胞との融合細胞でちるハイブリドーマＤ
ＩＯ株（注、正式にはＭ２５９０株でちる。）は黒色腫
瘍細胞と選択的に反応する抗体を分泌し、この抗体のタ
イプはＨ鎖についてはＩｇＭ型で、Ｌ鎖については！に
である。先づＤＩＯ株、　Ｐ３Ｕ１株及び０５７ＢＬ１
５マウス腎臓からＤＮｉ＆’ｉ単離す（Ｃｅｌ１２４３
５３〜３５６（１９８１）参照）次に１０μｍのＤＮＡ
を制限酵素ＨｉｎｄｌＪとＥｃｏＲＪで切断する。制限
酵素のＨＩｎｄｆＭで切断したＤＩＯ株とＰ３Ｕ１株及
び０５７　Ｂ　Ｌ／６マウス腎臓のＤＮＡを電気泳動で
０．９係のアガロースゲルに展開し、ニトロセルロース
膜（８ｃｈｌｅｉｃｈｅｒ　ａｎｄ　５ｃｈｖｅｌｌ　
ｌＪ、　Ｍｏ１．８ｉｏ１．９８５０３〜５１５（１９
７５）参照）に転写し、一方に領域を含んだ２．７　Ｋ
ｂ　Ｈｉｎｄｌｌｊ−Ｈｉｎｄｌｌｌ断片に相当する（
利根用進氏よ＃）得た。Ｎａｔｕｒｅ　２８０２８８〜
２９４（１９７９）参照）　Ｊにプローブ（１０’　ｃ
ｐｍｌｏ、ＩＤＮＡ）を用いたハイブリダゼーションを
行ったシの結果を図ＩＡ（ａ）に示す。
ところで図１＆（ａ）より明らかなようにＤＩＯ株のＤ
ＮＡは６．５　、６．３及び６．Ｉ　Ｋｂの３つの再配
列したバンドが存在する。これらのうち６．３及び６．
ＩＫｂはＰ３ＵＩ　ＤＮＡに見られるものと同様のもの
でちる。
６．５　ＫｂのバンドはＶに−Ｊに構造を含む活性な遺
伝子であり、その特異性の発現に関与する遺伝子でちる
。分子サイズはλフアージのＨｉｎｄｌＩ［マーカーに
よって見積った。このサイズに相当するＤＮＡ断片をア
ガロース電気泳動により単離し、λファージＨｉｎｄｌ
ｌベクターλ７８８　（Ｋ、　Ｍｕｒｒａｙ氏（ニシン
バラ大学）よシ得ｆ（、Ｍｏ１ｅ、　Ｇｅｎ、　Ｇｅｎ
ｅｔ、　１５０５３−６１（１９７７）参照）に挿入し
、λファージにパッケージした。パッケージマウスチャ
ーには大腸菌ＢＴ（８２６８８とＢＨＢ２６９０’に用
いた。（Ｈｏｈｎ。
Ｂ、Ｍｅｔｈ、　Ｅｎｚｙｍｏｌ　６８２９９−３０９
（１９７９）参照）次にＪにプローブをスクリーニング
に用いベントンディビス法（５ｃｉｅｎｃｅ　１９６１
８０−１８２（１９７７）参照）にしたがってブラーク
ツ１イブリダイゼーシヨンを行いクローンＶＪに１４を
単離した。
このクローンの制限酵素地図を表１８（ａ）に示す。
このクローンＶＪに１４のＨｌｎｄ　ｉｌｌ挿入断片を
ノーザンハイプリダイゼーションを行うために単離した
。
Ｄ１０株からグアニジニウムチオシアネート法（Ｂｉｏ
ｃｈｅｍｉｓｔｒｙ　１８５２９４〜５２９９　（１９
７９）参照）により全ＲＮＡを分離し、オリザｄＴセル
ロースカラムの素通シ画分からポリん構造をもつｍＲＮ
Ａを得た。図１ｘ（ｂ）はＤＩＯ株のｍＲＮＡと、クロ
ーンＶＪに１４のＨｌｎｄｌｌ）挿入断片或はＯに領域
を含む３Ｋｂ　Ｈｉｎｄｌｌ−ＢａｍＨＩ断片（利根用
進氏より得た。
Ｎａｔｕｒｅ　　２８０２８８−２９４　（１９７９）
　　参照）に相当スるＣにプローブとのノーザンノーイ
ブリダイゼーションを示している。Ｊ９と０５の両プロ
ーブにより１．２Ｋｂの位置にバンドが見つかった。
クローンＶＪに１４は機能的なＶに−Ｊに構造を含んで
いる。
ノーザンハイプリダイゼーションの方法は免疫実験操作
法ＸＩＩ（１９８３）に記載されている。
また１図１＆（ｃ）は０．９ＫｂのＸｂａｉ　−Ｂｃｏ
Ｒ）断片に相当するＪＨゾローブ（Ｃｅ１ｌ　２４３５
３−３６５（１９８１）参照）とＢｃｏＲｌで切断した
ＤＮＡのサザンハイブリダイゼーションを示す。先に述
べた理由を基にＤ１０株ＤＮ＆にだけ探索される５、５
　ＫｂのＤＮＡ１機能的なＨ鎖のＶ領域遺伝子を含む断
片λフアージＥＣ０ＲＴベクターであるλｇｔＷＥｓ−
λＢ（Ｐ、Ｌｅａｄｅｒ、５ｃｉｅｎｃｅ　１９６１７
５−１７７（１９７７）参照）を用いてクローン化し、
クローンＶＪＨ２４３を得た。クローンＶＪＨ２４３と
ＭＢＰ２０３　（Ｐｒｏｃ、Ｎａｔｌ、　＆ｃａｄ、Ｓ
ｃｆ、　Ｕ　Ｓ　Ａ　７７２１３８−２１４２（１９８
０）参照）の１０ＫｂのＥｃｏ几■断片に相当する０μ
プローブを用いた。
Ｄ１０株のｍＲＮＡとノーザンブロツテングｋ　行ツ＊
結果、　２．４Ｋｂの位置にバンドを見つけた（図１ｋ
（ｄ）参照）。りｏ　　７　ＶＪ　ｃ　１４　（！：　
ＶＪＨ２４３に含まれる活性なＶ遺伝子が特異性の発現
に関与する。
ヒトＯ遺伝子の単離 ヒトの血漿の中で主要な免疫グロブリンクラスでらるＩ
ｇＧの定常領域の遺伝子を単離する。すなわちヒトの免
疫グロブリン遺伝子の塩基配列はマウスのそれと高い相
同性を示しているので、ヒトのゲノムに存在する例えば
ＣにとＣγ１遺伝子をそれに相当するマウスの遺伝子を
プローブとして用いて単離するのであって、その方法は
クローンＩｇ１４６（Ｐｒｏｃ、Ｎａｔｌ＋＋入ｃａｄ
、Ｓｃｉ、ＵＳＡ７５４７０９−４７１３（１９７８）
参照）からの３ＫｂのＨｉｎｄ［［−ＢａｍＨＩ断片と
クローンＭＰ！　Ｐ　１０　（Ｐｒｏｃ、　Ｎａｔｌ。
Ａｃａｄ、Ｓｃｉ、ＵＳＡ、　７８４７４−４７８　（
１９８１）参照）からの６．８ＫｂのＥｃｏＲＪ断片を
プローブとして用いヒトのラムダｃｈａｒｏｎ　４　Ａ
のＨａｅ　ＩＩＩ　−Ａｌ　ｕＩ遺伝子ライブラリー（
Ｔ、　Ｎａｎ１ａｔｉｓ　Ｃｅ１１．１５　１１５７−
１１７４（１９７８）参照）中からヒトＣに遺伝子を含
みエンハンサ−領域を保持している断片を単離する。０
γ１遺伝子はヒト胎子単細胞ＤＮん’１ｚＨｉｎｄｌｉ
で切断しアガロースゲル電気泳動で太きさにしたがって
分画したのち５．９　ＫｂのパンＰをλ７８８に挿入し
前記のプローブを用いてクローン化した。単離したクロ
ーンは図Ｉ　Ｂ（ｃ）のＨＣに２と（ｄ）のＨＧ１６３
である。
工／ハンサーを保持し氷ヒトＣ９遺伝子を含む１．９　
ＫｂのＰｖｕ　ｌ断片を図Ｉ　Ｂ（ｃ）に示すクローン
Ｈ０，２から単離し等量混合した川ｎｄ　ｌ［とＢａｍ
Ｈｌから単離した６、５　Ｋｂ　のＨｉｎｄ　ｌ［挿入
断片と結合し、　ＢａｍＨ１で切断する。得られた断片
を分別しアガロースゲル電気泳動によｊｌ）　５．９　
Ｋｂ　　の断片を単する。この断片ｋ　ｐＳＶ２ｇｐｔ
の１３ａｍＨ１部位に挿入する。挿入した遺伝子の方向
は、制限地図によシ決定する。（図２　ａ　　ｐＳＶ２
−Ｈｏ、ＶＤ、。参照）８．２　Ｋｂ　ＯＨｉ　ｎ　ｄ
　Ｉｌｌ挿入断片’１ｋＨＧ１６３クローンから単離し
、Ｋｌｅｎｏｖ　　酵素によシ両端の一本鎖部分を消化
し、その両端にＥｃｏＲＩ　　！Ｊンカー（全酒造■製
）を接続した。その断片ヲＢｃｏ几工とＢａｍＨＩで切
断しＥＣＯＲＩとＢ’ａｍ　ＨＩで開環したプラスミＰ
ｐ８Ｖ２ｇｐｔに挿入し、ヒトＣγ１遺伝子を含むｐＳ
Ｖ２−）ＩＧ　１４クローンを得る。５．５　ＫｂのＥ
ｃｏ　ＲＩｌ断片りｏ　　ｙ　Ｖ　ＪＨ２４３から単離
しｐＳＶ２−ＨＧＩ　４（７）Ｅｃ　ｏＲＩ切断位置に
挿入する。挿入した遺伝子の方向に制限地図によシ決定
した。（図２　ｂ　　ｐＳＶ２−ＨＧＩＶＤｌ。
参照） ｐＳ　Ｖ　２　ＨＯＡ：ＶＤｌｏ　（！：　ｐＳ　Ｖ２
−ＨＧｔ　ＶＤｌｏ）両Ｄ　Ｎ　Ａ　ヲカルシウム、リ
ン酸共沈降法（ｐｒｏｃ、Ｎａｔｌ、Ａｃａｄ。
Ｓｃｉ、ＵＳＡ７６　１３７３−１３７６（１９７９参
照）によシプラズマサイトーマ（形質細胞腫）Ｐ２Ｏ３
株（Ｈ鎖は合成しないがＬ鎖を生産する性質を持つ）に
導入した。その方法は次のとおシである。
１、　　Ａ溶液をそれと等量の２ｘＨｅＢＳ溶液に滴下
する。
２、室温で３０分間保温する。
３、　　Ｐ３Ｏ１株にトリプシン処理゛し、細胞をばら
ばらにしｆｃ後１０チ牛脂児血清を含むＲＰＭ１１６４
０培地を加えトリプシン処理を終了させる。
４、培養液を１．５００　ｒｐｍ５分間遠心して細胞を
集める。
５、　牛胎児血清を含まない培地に２　Ｘ　Ｉ　Ｏ’個
の細胞を滴下する。
５、　１．５０　Ｏｒｐｍで５分間遠心する。
７　直接、１の液１０―に浮遊する。
８、３７℃で３０分間保温する。
９．５−を別の試験管に移す。
１０．１０チ牛脂児血清を含むＲＰＭ１１６４０の培地
をそれぞれ４５−ずつ加える０ １１．９６穴プレートにそれぞれ０．１−ずつ、イス１
０４清培地で培養する。
１３、ソノ後５μｔ／Ｉ＋７！のきコツエノール酸とザ ２５０μむ−のキサンチンを含むＭＭ１１６４０−１０
％牛脂児血清培地にとシかえ、形質転換した細胞を選択
する。
しかして、Ａ溶液及び２ｘＨｅＢ８溶液は次のような組
成を有する。
Ａ溶液 ２ｘＨｅＢＳ溶液　　　　ｐＨ７，０５ＨＥＰＦｉ８　
　　１０Ｗ／１ ＮａＯＡ　　　　１６ｆ／１ ＫＯｔ　　　　　Ｏ，７４り／１ Ｎａ２ＨＰ０４・Ｈ２Ｏ０，２５ｔ／１ｄｅｘｉｔｒｏ
ｓｅ　　　　２　ｔ／Ｚ選別 キメラモノクローナル抗体産生形質転換細胞の選別には
酵素免疫、蛍光抗体法、或はセルンーター（ＦＡＣ８）
（ペクトン・デンキンソン社）ニよる解析な用いた。ミ
コフェノール酸を含む選択培地により１８の形質転換細
胞クローンが選別された。Ｐ３Ｕ１株とこれら１８の形
質転換細胞はプレート中に十分増殖するまで選択培地で
育てた。
これらの細胞の培養上清を酵素免疫蛍光抗体法（Ｍｅｔ
ｈ、Ｅｎｚｙｍｏｌ、７０４１９−４３９　（１９８０
）参照）に１って抗体の産生状態を試験した。
その結果を表１に示す。
表　　１ ＨＭ）（−８１− ＨＭＨ−８６− ＨＭＨ−８７＋　　　　＋ ＨＭＨ−８８− ＨＭＨ−８１８− ＨＭＨ−８７はＩ　Ｘ　１０７ｆｌｉｉｌの細胞が１０
−の培養上清Ｉｃ　約１０　Ｏｎｆ／ｖｄ！のマウス・
ヒトキメラモノクローナル抗体を産生じている。
抗ヒトＩ　ｇ（）’ｉ用いｆｃＨＭＨ細胞とＰ３Ｕｙ）
セルンーター解析 ＨＭＨ細胞とＰ３Ｕ１株Ｇｄ　Ｉ−Ｔ　ａ　ｎ、ｋ　’
　ｓの平衡塩類溶液（Ｇｉｂｃｏ）で２度洗浄し１０７
個の細胞を７５０μｔの染色緩衝液（１％、　Ｆｅ２−
ＲＰＭＩｏ　、１１６４０　）と２５０μｔのウサギ抗
ヒト免疫グロブリン抗体又は正常ウサギＩｇＧ（１μｒ
／＋７りの混合液に浮遊させ、１時間室温で保温した。
その後細胞を３度洗浄した。その後の手順はベクターラ
ゼラトリ社のアビジンビオチンキット（ａｖｉｄｌｒｉ
ｅ　　ｂｉｏｔｉｎｅＩｃｉｔ）に示されているものと
同様である。要領としては細胞を予めヒト　ＩｇＧで吸
収処理したビオチン結合抗ウサギＩｇＧ（１，５ｍｆ／
ｍ１）２００倍希釈溶液２５０μｔに浮遊し、１時間、
室温で保温した後、Ｈａｎｋ’　ｓ溶液で３度洗浄し、
２５０μｔの２０倍希釈アビジンＦＩＴＣ（５ｍｆ／／
ｖｔ１．）に浮遊させ室温で３０分間保温し、Ｈａｎｋ
’ｓ溶液で３度洗浄する。
最後に１０６個の細胞’Ｔｈ１ｍｇの培養液に浮遊させ
、対数増幅器付きのＦＡＯ８■（ペクトン・ディクソン
社）で解析した。その結果を図３に示す。図３（ａ）　
ｔ　（ｂ）　＃　（Ｃ）は標的細胞としてＨＭＨ細胞を
用いウサギＩｇＧの反応をコントロールとし、それぞれ
（、）はウサギの抗ヒトＩｇ抗体、（ｂ）はウサギの抗
ヒトに抗体、（Ｃ）はウサギの抗ヒトＩｇＧＦｃ抗体と
の反応を表わし、（ｄ）　ｔ　（ｅ）　ｌ　（ｆ）はＨ
ＭＨ細胞とＰ　３Ｕ１細胞に対するそれぞれ（ｄ）はウ
サギの抗ヒトＩｇ抗体、（ｅ）はウサギの抗ヒトに抗体
、（ｆ）はウサギの抗ヒト　ＩｇＧ、Ｆｃ抗体の反応を
表わす。
ＨＭＨ細胞から前述の方法によ、９ＤＮＡとポリ。
入構造金含むＲＮＡを単離する・ＨＭＨ細胞の９Ｎ”と
同様に単離し７’ＣＯ５７ＢＬ／６腎臓細胞とＰ３Ｕ１
細胞のＤ　Ｎ　Ａ　ｆ　ＢａｍＨ’Ｉで切断しＪｚ（マ
ウス）プローブ（表４Ａ−（ａ））、Ｏに（ヒト）プロ
ーブ（表４Ａ　−（ｂ））　、　ＪＨ（マウス）プロー
ブ（衣４　Ａ　−（ｃ）　）及び０γ（ヒト）プローブ
（表４　Ａ　−（ａ）　）　ｗ用いサザンハイプリダイ
ゼーションを行う。
ヒトＣにとマウ刀にプローブはｐＳＶ２−ＨｅにＶＤＩ
。
のＢａｍＨＩ挿入断片のサイズに相当する５、９　Ｋｂ
のバンドｉ　ＨＭ　ＨＩＶｆＩ胞のＤＮＡ中に探索した
。マウスＪＨ７’ロ２ハｐＳＶ２−ＨＧＩＶＤＩＯ（７
）ＶＨ遺伝子を含むＥｃｏ几Ｉ挿入断片に相当する５、
５　Ｋｂのノ々ンドをＨＭ）（細胞のＤＮＡ中に探索し
た。ヒト０γ１　）０−フハｐＳＶ２−ＨＧＩＶＤｔｏ
のＣγ蹟伝子を含むＥｃｏ几Ｉ　−Ｂ　ａ　ｍ　ＨＩ挿
入断片ｉＨＭＨ細胞のＤＮＡ中に探索した。これらによ
υＨＭＨ細胞にはゲノム中に完全なＨ鎖とＬ鎖のキメラ
遺伝子を保持していることが示された。
ＨＭＨ細胞よシ単離したボＩＪ　Ａ構造をもつｍ−ＲＮ
ＡとＰ３Ｕ１よシ単離したポリ入構造をもつｍＲＮＡを
それぞれＶＪに１４ゾローブ、ヒトＯＬゾロープ、ＶＪ
Ｈ２４３プローブ及びヒトＣγ１ゾローブと９間でノー
ザンブロツテングを行った。ＶＪに１４プローブとヒト
０にプローブによシ通常に鎖を生産している細胞にみら
れるのと同じサイズに相当する１、２Ｋｌ）のバンドが
キメ２抗体のＬ鎖のｍ　ＲＮ　Ａとして探索され、Ｉ−
Ｉ　Ｍ　Ｈ細胞のｍ　ＲＮ　Ａ中に最初に転写されたも
ので、またスプライシングされていないためイントロン
がとり除かれていないｍ　ＲＮ　Ａが５ＫｂのパンＰと
して探索される。（図４　Ｂ　（ａ）（ｂ）参照）　Ｖ
ＪＨ２４３として０γ１ゾローブによ、りＨＭＨ細胞の
ｍＲＮＡ中に３．５Ｋｂと７Ｋｂのバンドが探索され、
３．５Ｋｂのバンドは膜結合盤のγＨ鎖のｍＲＮＡのサ
イズに相当し、７Ｋｂのバンドは最初に転写されイント
ロンがとシ除かれていないｍＲＮＡに相当する。
以上によ、ｉ５ＨＭＨ，ＩＢ胞中でマウス由来のＶ−（
Ｄ）−Ｊエクソンとヒト由来Ｏエクソンの間で最初に転
写されｆｒニー　ｍ　ＲＮ　Ａのスプライシングが部分
的に起っていることが証明された。
【図面の簡単な説明】
図１人は活性なマウスＶ遺伝子とヒトの０遺伝子を単離
するためのサザンハイプリダイゼーション及びそれらの
ｍ　ＲＮ　Ａのノーザンブロツテングの解析結果を示す
Ｘ線写真 Ｂは単離しｍクローンの制限酵素地図 図中Ｅｎはエンハンサ−１ＨはＨｉ　ｎ　ｄ　■、プラ
スミド構造 ａ）プラスミドｐＳＶ２−ＨＯＩｃＶＤｌｏの構造ｂ）
プラスミドｐＳＶ２−ＨＧＩＶＤｔｏ（Ｄ構造図３はセ
ルンーター解析図 図４ＡはＨＭＨ細胞のＤＮＡのサザンハイプリダイゼー
ション Ｂ１１１．ＨＭＨ細胞のｍ　ＲＮ　Ａのノーザンブロツ
テング解析結果を示すＸ線写真

Claims (7)

    【特許請求の範囲】
  1. （１）ヒト以外の動物由来の可変領域とヒト由来の定常
    領域からなるキメラモノクローナル抗体
  2. （２）ヒト以外の動物としてマウスである特許請求の範
    囲第１項記載のキメラモノクローナル抗体
  3. （３）ヒト以外の動物としてラットである特許請求の範
    囲第１項記載のキメラモノクローナル抗体
  4. （４）ヒト以外の動物の抗体産生細胞から単離した活性
    なＶ＿ＨとＶ＿Ｌ遺伝子及びヒトＤＮＡから単離したＣ
    ＿ＨとＣ＿Ｌ遺伝子を発現ベクターに挿入し、動物培養
    細胞に導入してキメラモノクローナル抗体を生産するこ
    とを特徴とするヒト以外の動物由来の可変領域とヒト由
    来の定常領域とからなるキメラモノクローナル抗体の製
    造方法
  5. （５）抗体産生細胞としてハイブリドーマ、エプスタイ
    ンバールヴイルスによる形質転換Ｂ細胞またはクローン
    化Ｂ細胞を用いる特許請求の範囲第４項記載のキメラモ
    ノクローナル抗体の製造方法
  6. （６）ベクターとしてｐＳＶ２−ｇｐｔ、ｐＳＶ２−ｎ
    ｅｏ、ＳＶ４０からなる群から選ばれたベクターを使用
    することからなる特許請求の範囲第４項記載のキメラモ
    ノクローナル抗体の製造方法
  7. （７）動物培養細胞がヒト、サル、マウス等の動物に由
    来するリンパ腫、腎細胞、Ｌ細胞、 ＣｏＳ細胞、ＨｅＬａ細胞の何れか一種を使用する特許
    請求の範囲第４項記載のキメラモノクローナル抗体の製
    造方法
JP16937084A 1984-08-15 1984-08-15 キメラモノクロ−ナル抗体及びその製造法 Granted JPS6147500A (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP16937084A JPS6147500A (ja) 1984-08-15 1984-08-15 キメラモノクロ−ナル抗体及びその製造法
DE19853587360 DE3587360T2 (de) 1984-08-15 1985-03-08 Verfahren zur Herstellung von chimärischen monoklonalen Antikörpern.
EP85102665A EP0171496B1 (en) 1984-08-15 1985-03-08 Process for the production of a chimera monoclonal antibody
DE1985102665 DE171496T1 (de) 1984-08-15 1985-03-08 Chimaerischer monoklonaler antikoerper und verfahren zu seiner herstellung.
CA 476731 CA1339201C (en) 1984-08-15 1985-03-18 Chimera monoclonal antibody and a production process thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP16937084A JPS6147500A (ja) 1984-08-15 1984-08-15 キメラモノクロ−ナル抗体及びその製造法

Publications (2)

Publication Number Publication Date
JPS6147500A true JPS6147500A (ja) 1986-03-07
JPH0373280B2 JPH0373280B2 (ja) 1991-11-21

Family

ID=15885326

Family Applications (1)

Application Number Title Priority Date Filing Date
JP16937084A Granted JPS6147500A (ja) 1984-08-15 1984-08-15 キメラモノクロ−ナル抗体及びその製造法

Country Status (4)

Country Link
EP (1) EP0171496B1 (ja)
JP (1) JPS6147500A (ja)
CA (1) CA1339201C (ja)
DE (2) DE3587360T2 (ja)

Cited By (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61119196A (ja) * 1984-08-27 1986-06-06 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　リ−ランド　スタンフオ−ド　ジユニア　ユニバ−シテイ Ｄｎａスプライシング及び発現によるキメラ性受容体
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
JPS6336786A (ja) * 1986-07-31 1988-02-17 Teijin Ltd 抗体ｌ鎖発現型核酸塩基配列，プラスミド，細胞及びキメラ抗体ｌ鎖
JPS6336796A (ja) * 1986-08-01 1988-02-17 Teijin Ltd マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
JPS63112995A (ja) * 1986-07-07 1988-05-18 セントコ−・インコ−ポレ−テッド 腫瘍関連抗原に特異的なキメラ齧歯類／ヒト免疫グロブリン
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
EP0327000A2 (en) 1988-01-30 1989-08-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Gene fragments coding for the variable region of an anti-HIV antibody, chimeric anti-HIV antibodies expressed using the same, and process for their preparation
JPH02501886A (ja) * 1986-10-27 1990-06-28 インターナショナル、ジェネティック、エンジニアリング、インコーポレーテッド ヒト腫瘍抗原に対し特異性を有するキメラ抗体
JPH02231567A (ja) * 1989-01-10 1990-09-13 Boehringer Mannheim Gmbh 血清又は血液中の物質を診断検出する方法
JPH02238883A (ja) * 1988-10-17 1990-09-21 Becton Dickinson & Co 抗―Ｌｅｕ　３ａアミノ酸配列
JPH03504556A (ja) * 1987-05-29 1991-10-09 タノツクス・バイオシステムズ・インコーポレーテツド Ｈｉｖ‐１を中和するモノクローナル抗体
JPH03254691A (ja) * 1990-03-02 1991-11-13 Japan Found Cancer Res 薬剤耐性癌に対するキメラ抗体およびその製造
JPH04501503A (ja) * 1988-05-18 1992-03-19 セントカー・インコーポレーテツド 血小板特異的キメラ免疫グロブリン
WO1992019759A1 (fr) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
JPH0584082A (ja) * 1990-10-18 1993-04-06 Boehringer Mannheim Gmbh 抗体遺伝子の可変部をコードするｄｎａフラグメントの単離法、キメラ抗体遺伝子の製法、キメラ抗体の取得法及び医薬の製法
JPH0690752A (ja) * 1990-10-17 1994-04-05 Wellcome Found Ltd:The 抗体産生
WO1994028159A1 (en) * 1993-05-31 1994-12-08 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
WO1995014041A1 (en) * 1993-11-19 1995-05-26 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
US5693493A (en) * 1985-11-01 1997-12-02 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5846818A (en) * 1985-11-01 1998-12-08 Xoma Corporation Pectate lyase signal sequence
US5877006A (en) * 1988-05-18 1999-03-02 Centocor, Inc. DNAs encoding chimeric immunoglobulin light or heavy chains and fragments thereof having variable regions derived from monoclonal antibody 7E3, and vectors and host cells comprising same
KR100266554B1 (ko) * 1993-01-14 2000-09-15 사꼬 미쓰오 재조합항-hiv항체및그의제조방법
US6790444B2 (en) 1991-03-18 2004-09-14 New York University Medical Center Anti-TNF antibodies and peptides of human necrosis factor
US7101674B2 (en) 1991-03-18 2006-09-05 New York University Anti-idiotypic anti-TNF antibodies and related immunoassay methods
US7128908B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
US7517963B2 (en) 1989-08-07 2009-04-14 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7605233B2 (en) 1989-08-07 2009-10-20 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7815909B2 (en) 2000-08-07 2010-10-19 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Families Citing this family (764)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
GB8422238D0 (en) * 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
WO1986005513A1 (en) * 1985-03-18 1986-09-25 Gene Labs, Inc. Hybrid-gene cassette vector
EP0536566A1 (en) * 1985-11-01 1993-04-14 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
GB2188941B (en) * 1986-04-14 1990-06-06 Bayer Ag Monoclonal antibodies recognizing human interleukin-2-receptor
CA1297434C (en) * 1986-04-14 1992-03-17 Kenji Murakami Method of producing peptides, recombinant plasmid for use in the same and animal cells transformed with the same
US4954617A (en) * 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
CA1340456C (en) * 1986-07-07 1999-03-23 Hubert J.P. Schoemaker Chimeric rodent/human immunoglobulins specific for tumor-associated antigens
US6893625B1 (en) 1986-10-27 2005-05-17 Royalty Pharma Finance Trust Chimeric antibody with specificity to human B cell surface antigen
IL85035A0 (en) * 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
ES2102347T3 (es) 1987-02-20 1997-08-01 Genentech Inc Metodos y composiciones para la utilizacion de polipeptidos env y anticuerpos anti-env de hiv.
US5091513A (en) * 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5258498A (en) * 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
AU612370B2 (en) * 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5132405A (en) * 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5981278A (en) * 1987-05-29 1999-11-09 Tanox, Inc. Chimeric monoclonal antibodies which neutralize HIV-1 infection and their applications in therapy and prevention for AIDS
US6657050B1 (en) 1987-05-29 2003-12-02 Tanox, Inc. Chimeric viral-neutralizing immunoglobulins
US5834599A (en) * 1987-05-29 1998-11-10 Tanox Biosystems, Inc. Immunoconjugates which neutralize HIV-1 infection
CA1341235C (en) * 1987-07-24 2001-05-22 Randy R. Robinson Modular assembly of antibody genes, antibodies prepared thereby and use
GB8720833D0 (en) * 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
US5843708A (en) * 1988-01-05 1998-12-01 Ciba-Geigy Corporation Chimeric antibodies
GB8800077D0 (en) * 1988-01-05 1988-02-10 Ciba Geigy Ag Novel chimeric antibodies
US5750375A (en) * 1988-01-22 1998-05-12 Zymogenetics, Inc. Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
EP0721983A1 (en) * 1988-01-22 1996-07-17 ZymoGenetics, Inc. Methods of producing biologically active peptide dimers
US5567584A (en) * 1988-01-22 1996-10-22 Zymogenetics, Inc. Methods of using biologically active dimerized polypeptide fusions to detect PDGF
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
JP3095168B2 (ja) * 1988-02-05 2000-10-03 エル． モリソン，シェリー ドメイン‐変性不変部を有する抗体
US5811265A (en) * 1988-08-19 1998-09-22 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
US5609869A (en) * 1988-08-19 1997-03-11 The General Hospital Corporation Hybrid immunoglobulin-thrombolytic enzyme molecules which specifically bind a thrombus, and methods of their production and use
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291160B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291161B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6969586B1 (en) 1989-05-16 2005-11-29 Scripps Research Institute Method for tapping the immunological repertoire
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6291159B1 (en) * 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5196320A (en) * 1989-09-20 1993-03-23 Abbott Biotech, Inc. Method of producing engineered binding proteins
US6750325B1 (en) 1989-12-21 2004-06-15 Celltech R&D Limited CD3 specific recombinant antibody
US7037496B2 (en) 1989-12-27 2006-05-02 Centocor, Inc. Chimeric immunoglobulin for CD4 receptors
US5958413A (en) * 1990-11-01 1999-09-28 Celltech Limited Use of antibodies to TNF or fragments derived thereof and xanthine derivatives for combination therapy and compositions therefor
CA2372251A1 (en) * 1991-01-21 1992-08-06 Michael John Mullan Test and model for alzheimer's disease
US5939531A (en) * 1991-07-15 1999-08-17 Novartis Corp. Recombinant antibodies specific for a growth factor receptor
ATE166578T1 (de) * 1991-07-25 1998-06-15 Idec Pharma Corp Anregung von antworten zytotoxischer t- lymphozyten
US5709860A (en) * 1991-07-25 1998-01-20 Idec Pharmaceuticals Corporation Induction of cytotoxic T-lymphocyte responses
CA2078539C (en) 1991-09-18 2005-08-02 Kenya Shitara Process for producing humanized chimera antibody
US5604102A (en) * 1992-04-15 1997-02-18 Athena Neurosciences, Inc. Methods of screening for β-amyloid peptide production inhibitors
US5441870A (en) * 1992-04-15 1995-08-15 Athena Neurosciences, Inc. Methods for monitoring cellular processing of β-amyloid precursor protein
US5851787A (en) * 1992-04-20 1998-12-22 The General Hospital Corporation Nucleic acid encoding amyloid precursor-like protein and uses thereof
US6610493B1 (en) 1993-06-17 2003-08-26 Brigham And Women's Hospital Screening compounds for the ability to alter the production of amyloid-β peptide
US6270766B1 (en) 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
US5605811A (en) * 1992-10-26 1997-02-25 Athena Neurosciences, Inc. Methods and compositions for monitoring cellular processing of beta-amyloid precursor protein
CA2153165C (en) * 1993-01-14 2003-05-06 Hiroaki Maeda Recombinant anti-hiv antibody and process for preparing the same
AU7732894A (en) * 1993-09-22 1995-04-10 Nichols Institute Diagnostics Graves' ophthalmopathy associated antibodies, graves' ophthalmopathy orbital antigen, and methods of use thereof
JPH09507746A (ja) 1993-10-27 1997-08-12 アテナ ニューロサイエンシズ，インコーポレイティド Ｓｗｅｄｉｓｈ変異を有するＡＰＰ対立遺伝子を含有するトランスジェニック動物
JPH10504441A (ja) 1994-03-07 1998-05-06 カイロン コーポレイション Ｔｎｆ形成阻害のための組成物およびその使用
US5874560A (en) 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US6576236B1 (en) 1994-07-01 2003-06-10 Dana Farber Cancer Institute Methods for stimulating T cell responses by manipulating a common cytokine receptor γ chain
US5614609A (en) * 1994-10-20 1997-03-25 Carlos F. Ibanez Serine threonine kinase receptor
NZ296748A (en) 1994-11-02 1999-11-29 Univ New York State Res Found Peripheral nervous system specific sodium channel proteins, DNA coding therefor, compositions and methods
US7597886B2 (en) 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
IL114615A0 (en) 1995-07-16 1995-11-27 Yeda Res & Dev Modulators of the function of fas receptors and other proteins
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
US6717031B2 (en) 1995-06-07 2004-04-06 Kate Dora Games Method for selecting a transgenic mouse model of alzheimer's disease
US7175847B1 (en) 1995-06-07 2007-02-13 Biogen Idec Inc. Treating intestinal inflammation with anti-CD80 antibodies that do not inhibit CD80 binding to CTLA-4
US7153508B2 (en) 1995-06-07 2006-12-26 Biogen Idec Inc. Treatment of B cell lymphoma using anti-CD80 antibodies that do not inhibit the binding of CD80 to CTLA-4
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
US6248555B1 (en) 1995-08-31 2001-06-19 The General Hospital Corporation Genetic alterations related to familial alzheimer's disease
JPH09124509A (ja) * 1995-10-27 1997-05-13 Sumitomo Electric Ind Ltd 肝炎治療剤
US7888466B2 (en) 1996-01-11 2011-02-15 Human Genome Sciences, Inc. Human G-protein chemokine receptor HSATU68
EP1865060B1 (en) 1996-07-12 2010-11-17 Institut National De La Sante Et De La Recherche Medicale (Inserm) Transcriptional Intermediary Factor-2
CA2264200A1 (en) 1996-08-16 1998-02-26 Human Genome Sciences, Inc. Human endokine alpha
DK0939804T4 (da) 1996-10-25 2011-07-18 Human Genome Sciences Inc Neutrokin-alpha
EP1780277A1 (en) 1997-01-15 2007-05-02 Yeda Research And Development Company, Ltd. IFN receptor 1 binding proteins, DNA encoding them, and methods of modulating cellular response to interferons
AU7019498A (en) 1997-04-10 1998-10-30 Diagnocure Inc. Pca3, pca3 genes, and methods of use
US6054567A (en) 1997-04-11 2000-04-25 The United States Of America As Represented By The Department Of Health And Human Services Recombinant proteins of a pakistani strain of hepatitis E and their use in diagnostic methods and vaccines
AU7137398A (en) 1997-04-16 1998-11-11 Millennium Pharmaceuticals, Inc. Crsp protein (cysteine-rich secreted proteins), nucleic acid molecules encoding them and uses therefor
ES2330393T3 (es) 1997-04-25 2009-12-09 Antigenics Inc. Caracterizacion de ehrlichia granulocitica y metodos de uso.
EP0977862B8 (en) 1997-04-30 2009-09-16 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
JP2002512521A (ja) 1997-05-30 2002-04-23 ヒューマン ジノーム サイエンシーズ，インコーポレイテッド ３２個のヒト分泌タンパク質
CA2206774A1 (en) 1997-06-16 1998-12-16 Rick E. Preddie "prionins", highly specific markers for noninvasive presymptomatic defection of tse diseases, and targets for therapeutic reagents to prevent and control tse diseases in animals and humans
PT2045322E (pt) 1997-07-14 2015-10-16 Université de Liège Musculatura dupla em mamíferos
DE19739685A1 (de) 1997-09-10 1999-03-11 Eichel Streiber Christoph Von Monoklonale Antikörper zur Therapie und Prophylaxe von Erkrankungen durch Clostridium difficile
ATE442385T1 (de) 1997-09-17 2009-09-15 Human Genome Sciences Inc Interleukin-17 rezeptor-ähnliches protein
ES2303358T3 (es) 1997-11-03 2008-08-01 Human Genome Sciences, Inc. Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral.
EP1093457B8 (en) 1998-03-19 2011-02-02 Human Genome Sciences, Inc. Cytokine receptor common gamma chain like
EP2357192A1 (en) 1999-02-26 2011-08-17 Human Genome Sciences, Inc. Human endokine alpha and methods of use
AU3382800A (en) 1999-02-26 2000-09-14 Millennium Pharmaceuticals, Inc. Secreted proteins and uses thereof
US6531125B1 (en) 1999-03-02 2003-03-11 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins
DE19915057A1 (de) 1999-04-01 2000-10-19 Forschungszentrum Borstel Monoklonale Antikörper gegen das humane Mcm3 Protein, Verfahren zu ihrer Herstellung und ihre Verwendung
CA2305716A1 (en) 1999-05-28 2000-11-28 University Of Guelph Method for assay of wbpm
IL130225A0 (en) 1999-05-31 2000-06-01 Yissum Res Dev Co Novel uses of antibodies against ache and peptides thereof
US20040001826A1 (en) 1999-06-30 2004-01-01 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
US7291714B1 (en) 1999-06-30 2007-11-06 Millennium Pharmaceuticals, Inc. Glycoprotein VI and uses thereof
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
CN102766210B (zh) 1999-08-24 2015-07-08 E.R.施贵宝&圣斯有限责任公司 人ctla-4抗体及其应用
ES2260059T3 (es) 1999-09-29 2006-11-01 Diagnocure Inc. Rna mensajero del pca3 en tejidos benignos y malignos de prostata.
US7892541B1 (en) 1999-09-30 2011-02-22 Tumor Biology Investment Group, Inc. Soluble epidermal growth factor receptor isoforms
EP1234031B2 (en) 1999-11-30 2021-11-24 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
JP2003521931A (ja) 2000-02-11 2003-07-22 バイオジェン インコーポレイテッド Ｔｎｆファミリーの異種ポリペプチド
EP1274720A4 (en) 2000-04-12 2004-08-18 Human Genome Sciences Inc FUSION PROTEINS CONTAINING ALBUMIN
US7560534B2 (en) 2000-05-08 2009-07-14 Celldex Research Corporation Molecular conjugates comprising human monoclonal antibodies to dendritic cells
EP1714661A3 (en) 2000-05-19 2012-03-14 The Center for Blood Research, INC. Methods for diagnosing and treating hemostatic disorders by modulating p-selectin activity
US20030031675A1 (en) 2000-06-06 2003-02-13 Mikesell Glen E. B7-related nucleic acids and polypeptides useful for immunomodulation
CA2410458A1 (en) 2000-06-08 2001-12-13 The Center For Blood Research, Inc. Methods and compositions for inhibiting immunoglobulin-mediated__reperfusion injury
WO2001096528A2 (en) 2000-06-15 2001-12-20 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
AU2001268427B2 (en) 2000-06-16 2007-03-29 Glaxosmithkline Intellectual Property Limited Antibodies that immunospecifically bind to blys
CA2420325A1 (en) 2000-08-25 2002-02-28 Basf Plant Science Gmbh Plant polynucleotides encoding novel prenyl proteases
JP2003000268A (ja) 2000-08-25 2003-01-07 Pfizer Prod Inc 血管新生にかかわる疾患を診断および治療するための方法および組成物
CA2417432C (en) 2000-09-01 2010-11-02 The Center For Blood Research, Inc. Modified polypeptides stabilized in a desired conformation and methods for producing same
UA83458C2 (uk) 2000-09-18 2008-07-25 Байоджен Айдек Ма Інк. Виділений поліпептид baff-r (рецептор фактора активації в-клітин сімейства tnf)
EP2174954B1 (en) 2000-10-18 2016-03-23 Robert Sackstein Hematopoietic cell e-selectin/l-selectin ligand polypeptides and methods of use thereof
JP2004515233A (ja) 2000-11-01 2004-05-27 イルーシス セラポーティクス，インコーポレーテッド タンパク質トランススプライシングによる二重特異性分子の作製方法
CA2429544C (en) 2000-11-17 2010-10-19 University Of Rochester In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells
US6989247B2 (en) 2000-11-28 2006-01-24 Celltech R & D, Inc. Compositions and methods for diagnosing or treating psoriasis
WO2002044419A2 (en) 2000-11-28 2002-06-06 Wyeth Expression analysis of kiaa nucleic acids and polypeptides useful in the diagnosis and treatment of prostate cancer
US6821731B2 (en) 2000-11-28 2004-11-23 Wyeth Expression analysis of FKBP nucleic acids and polypeptides useful in the diagnosis of prostate cancer
ATE506075T1 (de) 2000-12-08 2011-05-15 Curagen Corp Verfahren zur bestimmung und behandlung von tuberöse-sklerose komplex assoziierten erkrankungen
US7445802B2 (en) 2000-12-26 2008-11-04 Yeda Research And Development Co. Ltd Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
EP1373499B1 (en) 2001-02-23 2017-09-20 Dana-Farber Cancer Institute, Inc. Hin-1, a tumor suppressor gene
WO2002079499A1 (en) 2001-04-02 2002-10-10 Wyeth Pd-1, a receptor for b7-4, and uses therefor
CN1636062A (zh) 2001-04-16 2005-07-06 惠氏控股公司 编码多肽抗原的新肺炎链球菌可读框及其应用
US7256257B2 (en) 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US7745398B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 and treatment of cancer
US7744882B2 (en) 2001-05-31 2010-06-29 Tumor Biology Investment Group, Inc. Soluble ErbB3 methods of detection and antibodies
US7514078B2 (en) 2001-06-01 2009-04-07 Cornell Research Foundation, Inc. Methods of treating prostate cancer with anti-prostate specific membrane antigen antibodies
JP4619651B2 (ja) 2001-06-01 2011-01-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 前立腺特異的膜抗原に対する修飾抗体およびその使用
CA2450793A1 (en) 2001-06-20 2002-12-27 Prochon Biotech Ltd. Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof
US20040142325A1 (en) 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
ES2629395T3 (es) 2001-10-04 2017-08-09 Genetics Institute, Llc Métodos y composiciones para modular la actividad de la interleucina-21
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
DE10151511A1 (de) 2001-10-18 2003-05-08 Basf Lynx Bioscience Ag ee3-Proteinfamilie und zugrundeliegende DNA-Sequenzen
AU2002357770B2 (en) 2001-11-30 2008-07-31 Biogen Ma Inc. Antibodies against monocyte chemotactic proteins
GB0129105D0 (en) 2001-12-05 2002-01-23 Celltech R&D Ltd Expression control using variable intergenic sequences
US20060165683A1 (en) 2001-12-05 2006-07-27 Gerard Karsenty Methods and compositions for control of bone formation via modulation of sympathetic tone
AU2002361385B2 (en) 2001-12-18 2009-11-19 Centre National De La Recherche Scientifique Cnrs Novel death associated proteins of the THAP family and related Par4 pathways involved in apoptosis control
US7858297B2 (en) 2001-12-18 2010-12-28 Centre National De La Recherche Scientifique Cnrs Chemokine-binding protein and methods of use
WO2003054155A2 (en) 2001-12-19 2003-07-03 Bristol-Myers Squibb Company Pichia pastoris formate dehydrogenase and uses therefor
AU2002367317A1 (en) 2001-12-31 2003-07-24 Dana-Farber Cancer Institute, Inc. Psoriasin expression by breast epithelial cells
WO2003104428A2 (en) 2002-01-21 2003-12-18 Vaccinex, Inc. Gene differentially expressed in breast and bladder cancer and encoded polypeptides
ES2392247T3 (es) 2002-03-05 2012-12-07 Ramot At Tel-Aviv University Ltd. Compuesto inmunizante y método para inducir una respuesta inmune contra el sitio de escisión de la beta-secretasa de la proteína precursora de amiloide
GB0207533D0 (en) 2002-04-02 2002-05-08 Oxford Glycosciences Uk Ltd Protein
JP2005535572A (ja) 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
EP1499635B8 (en) 2002-05-02 2014-04-16 David Lovejoy Teneurin c-terminal associated peptides (tcap) and uses thereof
DE60232691D1 (de) 2002-05-07 2009-07-30 Agronomique Inst Nat Rech Screeningverfahren für PP1-wechselwirkende Polypeptide oder Proteine, Peptide, die die Bindung von PP1c an die Proteine Bcl-2, BCL-XL und BCL-W hemmen, und ihre Verwendung
JP4654029B2 (ja) 2002-06-17 2011-03-16 トラソス インコーポレイテッド 単一ドメインｔｄｆ関連化合物およびその類似体
US7250551B2 (en) 2002-07-24 2007-07-31 President And Fellows Of Harvard College Transgenic mice expressing inducible human p25
ES2544527T3 (es) 2002-07-31 2015-09-01 Seattle Genetics, Inc. Conjugados de fármacos y su uso para tratar el cáncer, una enfermedad autoinmune o una enfermedad infecciosa
EP2181595A1 (en) 2002-08-16 2010-05-05 Yeda Research And Development Company Ltd. Tumor associated antigen, peptides thereof, and use of same as anti-tumor vaccines
WO2004018999A2 (en) 2002-08-20 2004-03-04 Millenium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of cervical cancer
US7785608B2 (en) 2002-08-30 2010-08-31 Wyeth Holdings Corporation Immunogenic compositions for the prevention and treatment of meningococcal disease
EP2112229A3 (en) 2002-11-25 2009-12-02 Sequenom, Inc. Methods for identifying risk of breast cancer and treatments thereof
EP1581629B1 (en) 2002-12-06 2015-04-01 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with proteasome inhibition therapy
AU2003301148A1 (en) 2002-12-23 2004-07-22 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20050265992A1 (en) 2003-01-03 2005-12-01 The Research Foundation Of State University Of New York F11 receptor (F11R) antagonists as therapeutic agents
US8557957B2 (en) 2003-01-03 2013-10-15 Elizabeth Kornecki Methods of treating disorders by administration of F11 receptor antagonists
EP1595129A4 (en) 2003-01-17 2009-03-04 Univ Johns Hopkins METHOD FOR IDENTIFYING CELL GLYCOSYLATION MODULATORS USING GTRAP3-18
MXPA05007615A (es) 2003-01-21 2005-09-30 Bristol Myers Squibb Co Polinucleotido que codifica una novedosa acil coenzima a, monoacilglicerol aciltransferasa-3 (mgat3), y usos del mismo.
AU2004209578A1 (en) 2003-02-07 2004-08-19 Diagnocure Inc. Method to detect prostate cancer in a sample
US20040180387A1 (en) 2003-03-13 2004-09-16 Fujirebio Diagnostics, Inc. Detection of urinary mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of ovarian cancer
GB0309126D0 (en) 2003-04-17 2003-05-28 Neutec Pharma Plc Clostridium difficile focussed antibodies
DK2829283T3 (en) 2003-04-30 2017-09-18 Univ Zuerich METHOD OF TREATING CANCER USING IMMUNOTOXIN
CN1798769A (zh) 2003-05-12 2006-07-05 内蒂穆恩公司 抗masp－2抗体
US20050014932A1 (en) 2003-05-15 2005-01-20 Iogenetics, Llc Targeted biocides
US8080642B2 (en) 2003-05-16 2011-12-20 Vical Incorporated Severe acute respiratory syndrome DNA compositions and methods of use
US7892563B2 (en) 2003-05-20 2011-02-22 Wyeth Holdings Corporation Methods for treatment of severe acute respiratory syndrome (SARS)
CA2542232A1 (en) 2003-06-09 2005-01-20 Alnylam Pharmaceuticals, Inc. Method for treating neurodegenerative disease by inhibiting alpha-synuclein
JP5576010B2 (ja) 2003-08-04 2014-08-20 ザ・ホスピタル・フォー・シック・チルドレン ラフォラ病遺伝子
IL158287A0 (en) 2003-10-07 2004-05-12 Yeda Res & Dev Antibodies to nik, their preparation and use
CN102517381A (zh) 2003-10-07 2012-06-27 千年药品公司 用于鉴定、评价、预防和治疗卵巢癌的核酸分子和蛋白质
EP3434275A1 (en) 2003-11-06 2019-01-30 Seattle Genetics, Inc. Assay for cancer cells based on the use of auristatin conjugates with antibodies
US20050215634A1 (en) 2003-11-11 2005-09-29 Schlievert Patrick M Regulation of cell membrane-mediated effects
US7427670B2 (en) 2003-12-19 2008-09-23 Cytochroma Inc. Cytochrome P450 24 (CYP24) monoclonal antibody and methods and uses thereof
AU2004309257A1 (en) 2003-12-30 2005-07-14 Suntory Holdings Limited Novel serum type streptococcus mutans and utilization of the same
AU2005205533B2 (en) 2004-01-07 2012-03-22 Novartis Vaccines And Diagnostics, Inc. M-CSF-specific monoclonal antibody and uses thereof
US20060014211A1 (en) 2004-01-21 2006-01-19 Fujirebio Diagnostics, Inc. Detection of mesothelin-/megakaryocyte potentiating factor-related peptides for assessment of the peritoneum and the peritoneal cavity
EP2857418B1 (en) 2004-02-06 2017-07-26 University of Massachusetts Antibodies against Clostridium difficile toxins and uses thereof
CA2560066A1 (en) 2004-03-01 2005-09-15 The Cbr Institute For Biomedical Research, Inc. Natural igm antibodies and inhibitors thereof
BRPI0509201A (pt) 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
CA2561686C (en) 2004-03-31 2014-12-02 Genentech, Inc. Humanized anti-tgf-beta antibodies
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
US20060024670A1 (en) 2004-05-18 2006-02-02 Luke Catherine J Influenza virus vaccine composition and methods of use
AU2005247943A1 (en) 2004-05-23 2005-12-08 Gerard M. Housey Theramutein modulators
CA2897218A1 (en) 2004-06-17 2006-01-26 Thrasos Innovation, Inc. Tdf-related compounds and analogs thereof
GB0414054D0 (en) 2004-06-23 2004-07-28 Owen Mumford Ltd Improvements relating to automatic injection devices
CA2574654C (en) 2004-07-22 2014-02-18 Five Prime Therapeutics, Inc. Compositions and methods of use for mgd-csf in disease treatment
TWI374935B (en) 2004-08-27 2012-10-21 Pfizer Ireland Pharmaceuticals Production of α-abeta
US7300773B2 (en) 2004-08-27 2007-11-27 Wyeth Research Ireland Limited Production of TNFR-Ig
TWI384069B (zh) 2004-08-27 2013-02-01 Pfizer Ireland Pharmaceuticals 多胜肽之製法
DK3428191T3 (da) 2004-10-06 2025-01-02 Mayo Found Medical Education & Res B7-h1 og pd-1 til behandling af renalcellekarcinom
JP2008519863A (ja) 2004-11-12 2008-06-12 シアトル ジェネティクス インコーポレイティッド Ｎ末端にアミノ安息香酸単位を有するオーリスタチン
CA2491067A1 (en) 2004-12-24 2006-06-24 Stichting Katholieke Universiteit Mrna rations in urinary sediments and/or urine as a prognostic marker for prostate cancer
GT200600031A (es) 2005-01-28 2006-08-29 Formulacion anticuerpo anti a beta
CN101160528A (zh) 2005-02-14 2008-04-09 惠氏公司 Il17-f在诊断和治疗气道炎症中的用途
EP3312196B1 (en) 2005-03-23 2019-07-17 Genmab A/S Antibodies against cd38 for treatment of multiple myeloma
GT200600148A (es) 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EP1871418B1 (en) 2005-04-19 2014-03-19 Seattle Genetics, Inc. Humanized anti-cd70 binding agents and uses thereof
WO2006117782A2 (en) 2005-05-04 2006-11-09 Quark Pharmaceuticals, Inc. Recombinant antibodies against cd55 and cd59 and uses thereof
US8431110B2 (en) 2005-05-23 2013-04-30 Hmi Medical Innovations, Llc. Compounds and method of identifying, synthesizing, optimizing and profiling protein modulators
US20100074884A1 (en) 2005-05-31 2010-03-25 Duska Scientific Co. Inhibition of neuronal damage
BRPI0611600B8 (pt) 2005-06-17 2021-05-25 Wyeth Corp método para purificação de uma proteína tendo uma região fc a partir de um líquido fonte compreendendo a proteína e uma ou mais impurezas, e kit
JP5171621B2 (ja) 2005-07-07 2013-03-27 シアトル ジェネティックス， インコーポレイテッド フェニルアラニン側鎖修飾をｃ末端に有するモノメチルバリン化合物
SI1912671T1 (en) 2005-07-18 2018-01-31 Seattle Genetics, Inc. Conjugates beta-glucuronide linker-drug
WO2007009469A2 (en) 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an fc receptor
WO2007016285A2 (en) 2005-07-28 2007-02-08 Novartis Ag M-csf specific monoclonal antibody and uses thereof
PT2497780E (pt) 2005-09-20 2015-08-20 Thrasos Innovation Inc Compostos relacionados com tdf e seus análogos
EP1940231B1 (en) 2005-09-28 2011-05-04 Becton, Dickinson & Company Detection of lysophosphatidylcholine for prognosis or diagnosis of a systemic inflammatory condition
WO2007050793A2 (en) 2005-10-25 2007-05-03 The Johns Hopkins University Methods and compositions for the treatment of marfan syndrome and associated disorders
PT1948235E (pt) 2005-11-01 2013-11-26 Abbvie Biotechnology Ltd Métodos de determinação da eficácia de adalimumab em sujeitos com espondilite anquilosante, utilizando ctx-ii e mmp3 como biomarcadores
ZA200804082B (en) 2005-11-07 2010-02-24 Scripps Research Inst Compositions and methods for controlling tissue factor signaling specificity
AU2006311458C1 (en) 2005-11-10 2013-05-09 Board Of Supervisors Of Louisiana State University & Agricultural & Mechanical College Compositions and methods for the treatment of addiction and other neuropsychiatric disorders
WO2007059166A2 (en) 2005-11-14 2007-05-24 Weber Georg F Peptide sequence that promotes tumor invasion
US10183986B2 (en) 2005-12-15 2019-01-22 Industrial Technology Research Institute Trimeric collagen scaffold antibodies
US20070264687A1 (en) 2005-12-15 2007-11-15 Min-Yuan Chou Recombinant triplex scaffold-based polypeptides
WO2008029281A2 (en) 2006-02-10 2008-03-13 Invitrogen Corporation Labeling and detection of post translationally modified proteins
WO2007094472A1 (ja) 2006-02-17 2007-08-23 Atsuo Sekiyama 生体負荷の指標剤および生体負荷の測定方法
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
SI1854477T1 (sl) 2006-03-16 2017-01-31 Dyax Corp. Peptidi, ki inhibirajo plazma kalikrein za uporabo pri zdravljenju očesnih motenj
AU2007241130A1 (en) 2006-03-31 2007-11-01 EMD Serono Research Centre, Inc. Treatment of tumors expressing mutant EGF receptors
EP2738179A1 (en) 2006-04-05 2014-06-04 AbbVie Biotechnology Ltd Antibody purification
EP2708242A3 (en) 2006-04-10 2014-03-26 Abbott Biotechnology Ltd Uses and compositions for treatment of ankylosing spondylitis
EP2666472A3 (en) 2006-04-10 2014-04-02 Abbott Biotechnology Ltd Uses and compositions for treatment of psoriatic arthritis
CA2564435A1 (en) 2006-04-10 2007-10-10 Abbott Biotechnology Ltd. Methods for monitoring and treating intestinal disorders
WO2007124133A2 (en) 2006-04-20 2007-11-01 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Incorporated Methods and compositions based on shiga toxin type 1 protein
WO2007140599A1 (en) 2006-06-05 2007-12-13 Cancer Care Ontario Assessment of risk for colorectal cancer
GB0611116D0 (en) 2006-06-06 2006-07-19 Oxford Genome Sciences Uk Ltd Proteins
WO2007144893A2 (en) 2006-06-15 2007-12-21 Fibron Ltd. Antibodies blocking fibroblast growth factor receptor activation and methods of use thereof
PT2193801E (pt) 2006-06-28 2012-02-28 Yeda Res & Dev Caspase-8 e tratamento de inflamação, infecção e cicatrização de ferida
US7572618B2 (en) 2006-06-30 2009-08-11 Bristol-Myers Squibb Company Polynucleotides encoding novel PCSK9 variants
TWI498137B (zh) 2006-06-30 2015-09-01 Abbvie Biotechnology Ltd 自動注射裝置
EP2046383B1 (en) 2006-07-04 2014-11-19 Genmab A/S Cd20 binding molecules for the treatment of copd
KR101495549B1 (ko) 2006-07-13 2015-02-25 와이어쓰 엘엘씨 당단백질의 생산
JP5406027B2 (ja) 2006-08-04 2014-02-05 ノバルティス アーゲー ＥｐｈＢ３特異的抗体およびその使用
EP3018144A1 (en) 2006-08-18 2016-05-11 XOMA Technology Ltd. Prlr-specific antibody and uses thereof
US7951776B2 (en) 2006-09-01 2011-05-31 American Type Culture Collection Methods for treatment of type 1 diabetes
US20090203602A1 (en) 2006-09-01 2009-08-13 Cohava Gelber Compositions and methods for diagnosis and treatment of type 2 diabetes
AU2007302448C1 (en) 2006-09-26 2019-02-14 Genmab A/S Combination treatment of CD38-expressing tumors
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
MX2009003542A (es) 2006-10-12 2009-04-15 Wyeth Corp Metodos y composiciones con opalescencia reducida.
US8192951B2 (en) 2006-11-03 2012-06-05 Wyeth Llc Glycolysis-inhibiting substances in cell culture
US20110294782A1 (en) 2006-11-10 2011-12-01 Massachusetts Institute Of Technology Small molecule pak inhibitors
JP2010510235A (ja) 2006-11-15 2010-04-02 ファンクショナル・ジェネティクス・インコーポレーテッド 抗ｔｓｇ１０１抗体およびウイルス感染の処置のためのその使用
JP5279504B2 (ja) 2006-11-17 2013-09-04 一般財団法人阪大微生物病研究会 神経伸長促進剤および伸長阻害剤
DK2099823T4 (da) 2006-12-01 2022-05-09 Seagen Inc Målbindingsmiddelvarianter og anvendelser deraf
KR20140119831A (ko) 2006-12-07 2014-10-10 노파르티스 아게 Ｅｐｈｂ３에 대한 길항제 항체
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
CA2674788A1 (en) 2007-01-08 2008-07-17 Government Of The Usa, As Represented By The Secretary, Department Of He Alth And Human Services Slco1b3 genotype
JP5361738B2 (ja) 2007-01-22 2013-12-04 ジェネンテック， インコーポレイテッド 多価電解質沈殿物及びタンパク質の精製
WO2008104803A2 (en) 2007-02-26 2008-09-04 Oxford Genome Sciences (Uk) Limited Proteins
EP2447719B1 (en) 2007-02-26 2016-08-24 Oxford BioTherapeutics Ltd Proteins
RU2009132986A (ru) 2007-03-02 2011-04-10 Уайт (Us) Применение меди и глутамата в культуре клеток для производства полипептидов
US20110189663A1 (en) 2007-03-05 2011-08-04 Cancer Care Ontario Assessment of risk for colorectal cancer
TW200902708A (en) 2007-04-23 2009-01-16 Wyeth Corp Methods of protein production using anti-senescence compounds
JP6071165B2 (ja) 2007-05-31 2017-02-01 ゲンマブ エー／エス 安定なＩｇＧ４抗体
US8999337B2 (en) 2007-06-11 2015-04-07 Abbvie Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis by inhibition of TNFα
US20080317768A1 (en) 2007-06-21 2008-12-25 Boeing Company Bioconjugated nanoparticles
EP2185688A4 (en) 2007-08-06 2010-08-25 Burnham Inst Medical Research ZNF206: A NEW REGULATOR OF SELF-RENEWAL AND PLURIPOTENCE OF EMBRYONIC STEM CELLS
US7951785B2 (en) 2007-09-21 2011-05-31 California Institute Of Technology NFIA in glial fate determination, glioma therapy and astrocytoma treatment
EP2573104A1 (en) 2007-09-24 2013-03-27 Cornell University Immunogenic proteins form genome-derived outer membrane of leptospira and compositions and methods based thereon
CN101809153B (zh) 2007-09-27 2014-01-01 日本烟草产业株式会社 参与疱疹病毒的潜伏感染的因子及其利用
GB0719231D0 (en) 2007-10-03 2007-11-14 Oxford Genome Sciences Uk Ltd Protein
PT2237803E (pt) 2007-12-28 2015-10-16 Prothena Biosciences Ltd Tratamento e profilaxia da amiloidose
CA3108119C (en) 2008-01-15 2024-01-16 The Board Of Trustees Of The Leland Stanford Junior University Markers of acute myeloid leukemia stem cells
MX2010008083A (es) 2008-01-25 2010-12-20 Univ Aarhus Inhibicion de exositios selectivos de actividad papp-a contra igfbp-4.
EP2265283B1 (en) 2008-03-18 2014-09-03 Seattle Genetics, Inc. Auristatin drug linker conjugates
ES2651924T3 (es) 2008-04-18 2018-01-30 The General Hospital Corporation Inmunoterapias que emplean vacunas autoensamblantes
CN102076865B (zh) 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
US8741287B2 (en) 2008-06-18 2014-06-03 Abbott Laboratories PlGF-1 assay and kits and components thereof
RU2010151562A (ru) 2008-06-20 2012-07-27 ВАЙЕТ ЭлЭлСи (US) Композиции и способы применения orf1358 из бета-гемолитических стрептококковых штаммов
US8460657B2 (en) 2008-06-25 2013-06-11 H. Lundbeck A/S Modulation of the TrpV: Vps10p receptor system for the treatment of pain
JP2011527572A (ja) 2008-07-09 2011-11-04 バイオジェン・アイデック・エムエイ・インコーポレイテッド Ｌｉｎｇｏ抗体または断片を含む組成物
US20100075329A1 (en) 2008-09-23 2010-03-25 O'toole Margot Methods for predicting production of activating signals by cross-linked binding proteins
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
SMT202000101T1 (it) 2008-10-10 2020-03-13 Childrens Medical Center Vaccino con trimero di env di hiv-1 stabilizzato biochimicamente
CA2739352C (en) 2008-10-29 2021-07-13 Wyeth Llc Methods for purification of single domain antigen binding molecules
KR101593285B1 (ko) 2008-10-29 2016-02-11 아블린쓰 엔.브이. 단일 도메인 항원 결합 분자의 제형
CN107050442B (zh) 2008-11-05 2022-09-13 惠氏有限责任公司 用于预防β-溶血链球菌(BHS)疾病的多组分免疫原性组合物
WO2010062995A2 (en) 2008-11-26 2010-06-03 Five Prime Therapeutics, Inc. Compositions and methods for regulating collagen and smooth muscle actin expression by serpine2
AU2009323996A1 (en) 2008-12-03 2011-07-07 Institut Pasteur Use of phenol-soluble modulins for vaccine development
US8703125B2 (en) 2008-12-19 2014-04-22 H. Lundbeck A/S Modulation of the Vps10p-domain receptor family for the treatment of mental and behavioural disorders
US8349325B2 (en) 2008-12-23 2013-01-08 Abbott Laboratories Soluble FMS-like tyrosine kinase-1 (sFLT-1) antibody and related composition, kit, methods of using, and materials and method for making
EP2382238A1 (en) 2008-12-31 2011-11-02 Biogen Idec MA Inc. Anti-lymphotoxin antibodies
WO2010080985A1 (en) 2009-01-08 2010-07-15 Dana-Farber Cancer Institute, Inc. Compositions and methods for induced brown fat differentiation
CA2750581A1 (en) 2009-01-21 2010-07-29 Oxford Biotherapeutics Ltd. Pta089 protein
US8530629B2 (en) 2009-01-30 2013-09-10 Ab Biosciences, Inc. Lowered affinity antibodies and uses therefor
US9085795B2 (en) 2009-02-04 2015-07-21 Molecular Innovations, Inc. Methods for screening candidate agents for modulating prorenin and renin, assays for detecting prorenin and antibodies
JP2010213694A (ja) 2009-03-12 2010-09-30 Wyeth Llc ＰＫＮ３／ＲｈｏＣ高分子複合体およびその使用方法
US20120070450A1 (en) 2009-03-24 2012-03-22 Riken Leukemia stem cell markers
WO2010112034A2 (en) 2009-04-02 2010-10-07 Aarhus Universitet Compositions and methods for treatment and diagnosis of synucleinopathies
EP3248618A1 (en) 2009-04-22 2017-11-29 Massachusetts Institute Of Technology Innate immune suppression enables repeated delivery of long rna molecules
US20120294868A1 (en) 2009-04-24 2012-11-22 Edwards James R Anti-tgf-beta induction of bone cell function and bone growth
JP5925116B2 (ja) 2009-04-29 2016-05-25 ザ・ヘンリー・エム・ジャクソン・ファンデイション・フォー・ジ・アドヴァンスメント・オヴ・ミリタリー・メディシン、インコーポレイテッド Ｅｒｇモノクローナル抗体
MX2011011541A (es) 2009-04-29 2012-02-28 Abbott Biotech Ltd Dispositivo de inyeccion automatico.
EP2272979A1 (en) 2009-06-30 2011-01-12 Centre National de la Recherche Scientifique (CNRS) Method for testing a subject thought to be predisposed to having cancer
CN102481380A (zh) 2009-07-09 2012-05-30 霍夫曼-拉罗奇有限公司 体内肿瘤血管系统成像
EP2470564A1 (en) 2009-10-22 2012-07-04 Yeda Research and Development Co. Ltd. Compositions and methods for treating aspergillosis
US20120282177A1 (en) 2009-11-02 2012-11-08 Christian Rohlff ROR1 as Therapeutic and Diagnostic Target
WO2011054359A2 (en) 2009-11-06 2011-05-12 University Of Copenhagen Method for early detection of cancer
US8968740B2 (en) 2009-11-13 2015-03-03 Dana-Farber Cancer Institute, Inc. Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1
US8758301B2 (en) 2009-12-15 2014-06-24 Abbvie Biotechnology Ltd Firing button for automatic injection device
EP2513144A1 (en) 2009-12-16 2012-10-24 Philip Bosch Methods of treating interstitial cystitis
WO2011091134A2 (en) 2010-01-22 2011-07-28 Dana-Farber Cancer Institute, Inc. Compositions,kits, and methods for identification, assessment, prevention, and therapy of metabolic disorders
WO2011094593A2 (en) 2010-01-28 2011-08-04 Ab Biosciences, Inc. Novel lowered affinity antibodies and methods of marking the same
WO2011097301A2 (en) 2010-02-02 2011-08-11 Abbott Biotechnology Ltd. METHODS AND COMPOSITIONS FOR PREDICTING RESPONSIVENESS TO TREATMENT WITH TNF-α INHIBITOR
TWI518325B (zh) 2010-02-04 2016-01-21 自治醫科大學 對ａｌｋ抑制劑具有先抗性或後抗性癌症的識別、判斷和治療
KR101900110B1 (ko) 2010-02-10 2018-09-18 후지필름 알아이 파르마 가부시키가이샤 방사성 금속 표지 항카드헤린 항체
SG183854A1 (en) 2010-03-03 2012-10-30 Univ British Columbia Oligomer-specific amyloid beta epitope and antibodies
WO2011119484A1 (en) 2010-03-23 2011-09-29 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
WO2013040142A2 (en) 2011-09-16 2013-03-21 Iogenetics, Llc Bioinformatic processes for determination of peptide binding
US20150231215A1 (en) 2012-06-22 2015-08-20 Randolph J. Noelle VISTA Antagonist and Methods of Use
US10745467B2 (en) 2010-03-26 2020-08-18 The Trustees Of Dartmouth College VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders
MX342017B (es) 2010-03-26 2016-09-09 Dartmouth College Proteina mediadora de celula t regulatoria vista, agentes de enlace de vista y uso de los mismos.
WO2011125012A1 (en) 2010-04-05 2011-10-13 Wyeth Llc Biomarkers for p13k-driven cancer
KR101850687B1 (ko) 2010-04-21 2018-04-20 애브비 바이오테크놀로지 리미티드 치료제의 제어된 전달을 위한 착용형 자동 주사 디바이스
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
CA2801917C (en) 2010-06-03 2017-04-25 Abbvie Biotechnology Ltd Uses and compositions for treatment of hidradenitis suppurativa (hs)
WO2012009705A1 (en) 2010-07-15 2012-01-19 Zyngenia, Inc. Ang-2 binding complexes and uses thereof
WO2012007880A2 (en) 2010-07-16 2012-01-19 Ablynx Nv Modified single domain antigen binding molecules and uses thereof
EP2420250A1 (en) 2010-08-13 2012-02-22 Universitätsklinikum Münster Anti-Syndecan-4 antibodies
WO2012023085A1 (en) 2010-08-20 2012-02-23 Wyeth Llc Cell culture of growth factor-free adapted cells
RU2580620C2 (ru) 2010-08-23 2016-04-10 ВАЙЕТ ЭлЭлСи СТАБИЛЬНЫЕ КОМПОЗИЦИИ АНТИГЕНОВ Neisseria meningitidis rLP2086
WO2012032489A1 (en) 2010-09-10 2012-03-15 Wyeth Llc Non-lipidated variants of neisseria meningitidis orf2086 antigens
UA112062C2 (uk) 2010-10-04 2016-07-25 Бьорінгер Інгельхайм Інтернаціональ Гмбх Cd33-зв'язувальний агент
US9539427B2 (en) 2010-11-08 2017-01-10 The Johns Hopkins University Methods for improving heart function
US20120115244A1 (en) 2010-11-09 2012-05-10 Abbott Laboratories Materials and methods for immunoassay of pterins
EP2643454A4 (en) 2010-11-24 2014-05-21 Hong Gao EXPANSION OF HEMATOPOETIC STEM CELLS
US20150018408A1 (en) 2013-07-10 2015-01-15 The Regents Of The University Of Michigan Therapeutic antibodies and uses thereof
WO2012096960A2 (en) 2011-01-10 2012-07-19 The Regents Of The University Of Michigan Stem cell factor inhibitor
RU2602039C2 (ru) 2011-01-24 2016-11-10 Эббви Байотекнолоджи Лтд. Автоматические инъекционные устройства, имеющие наформованные поверхности захвата
PH12013501802B1 (en) 2011-03-02 2018-06-27 Berg Llc Interrogatory cell-based assays and uses thereof
CN106039306A (zh) 2011-03-30 2016-10-26 埃博灵克斯股份有限公司 使用针对TNFα的单结构域抗体治疗免疫病症的方法
US20120328567A1 (en) 2011-04-08 2012-12-27 Steven Bushnell Biomarkers predictive of therapeutic responsiveness to ifnb and uses thereof
WO2012145746A1 (en) 2011-04-21 2012-10-26 The Regents Of The University Of Colorado, A Body Corporate Compositions and methods for the treatment of neuromyelitis optica
CN103619378B (zh) 2011-04-21 2017-03-01 艾伯维公司 可佩戴式自动注射装置
EP2714738B1 (en) 2011-05-24 2018-10-10 Zyngenia, Inc. Multivalent and monovalent multispecific complexes and their uses
PL2726094T3 (pl) 2011-06-28 2017-06-30 Oxford Biotherapeutics Ltd Cel terapeutyczny i diagnostyczny
US20150125533A1 (en) 2011-07-25 2015-05-07 American University In Cairo Single-domain antibodies and graphene coated magnetic metal nanoparticles conjugate and methods for using the same
BR112014004162A2 (pt) 2011-08-22 2018-04-24 Cangene Corp anticorpos contra clostridium difficile
ES2704126T3 (es) 2011-08-23 2019-03-14 Found Medicine Inc Moléculas de fusión KIF5B-RET y usos de las mismas
WO2013036596A2 (en) 2011-09-06 2013-03-14 Reed Guy L Serpinf2-binding molecules and methods of use
US10093705B2 (en) 2011-09-13 2018-10-09 Dana-Farber Cancer Institute, Inc. Compositions and methods for brown fat induction and activity using FNDC5
WO2013041687A1 (en) 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
WO2013056178A2 (en) 2011-10-14 2013-04-18 Foundation Medicine, Inc. Novel estrogen receptor mutations and uses thereof
WO2013059740A1 (en) 2011-10-21 2013-04-25 Foundation Medicine, Inc. Novel alk and ntrk1 fusion molecules and uses thereof
CA2852021C (en) 2011-10-21 2018-08-28 Pfizer Inc. Addition of iron to improve cell culture
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
TWI589592B (zh) 2011-11-17 2017-07-01 輝瑞股份有限公司 胞毒性肽類以及其抗體藥物共軛體
EP2783214A2 (en) 2011-11-23 2014-10-01 The Board of Regents of The University of Texas System Proteomic identification of antibodies
EP2599496A1 (en) 2011-11-30 2013-06-05 Kenta Biotech AG Novel targets of Acinetobacter baumannii
ES2680151T3 (es) 2012-03-01 2018-09-04 Amgen Research (Munich) Gmbh Moléculas de unión de polipéptidos de larga duración
SA115360586B1 (ar) 2012-03-09 2017-04-12 فايزر انك تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
CA2865745C (en) 2012-03-09 2018-01-09 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
US9700857B1 (en) 2012-03-23 2017-07-11 Life Technologies Corporation Fluid mixing system with drive shaft steady support
RU2017139267A (ru) 2012-03-27 2019-02-12 Дженентек, Инк. Усовершенствованные способы выделения рекомбинантных белков
WO2013152011A1 (en) 2012-04-02 2013-10-10 Ab Biosciences, Inc. Novel human control antibodies and uses therefor
AU2012376214B2 (en) 2012-04-02 2019-02-14 Berg Llc Interrogatory cell-based assays and uses thereof
MX381731B (es) 2012-05-14 2025-03-13 Biogen Ma Inc Antagonistas de proteina que interactua con el receptor nogo 2 que contiene repeticion rica en leucina y dominio de inmunoglobulina (lingo-2) para el tratamiento de afecciones que involucran neuronas motoras.
AU2013263002C1 (en) 2012-05-15 2018-05-31 Seagen Inc. Self-stabilizing linker conjugates
US9890215B2 (en) 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
GB201213652D0 (en) 2012-08-01 2012-09-12 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
US10457733B2 (en) 2012-08-03 2019-10-29 Dana-Farber Cancer Institute, Inc. Agents that modulate immune cell activation and methods of use thereof
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
EP2903692B1 (en) 2012-10-08 2019-12-25 St. Jude Children's Research Hospital Therapies based on control of regulatory t cell stability and function via a neuropilin-1:semaphorin axis
CN104870014A (zh) 2012-10-09 2015-08-26 比奥根Ma公司 联合治疗及用于治疗脱髓鞘病症的用途
US20150246146A1 (en) 2012-10-25 2015-09-03 Life Technologies Corporation Methods and compositions for enzyme-mediated site-specific radiolabeling of glycoproteins
WO2014071419A2 (en) 2012-11-05 2014-05-08 Foundation Medicine, Inc. Novel fusion molecules and uses thereof
ES2656298T3 (es) 2012-11-05 2018-02-26 Pfizer Inc. Análogos de ayustoestatina
AU2013337277B2 (en) 2012-11-05 2018-03-08 Foundation Medicine, Inc. Novel NTRK1 fusion molecules and uses thereof
CA2890571A1 (en) 2012-11-07 2014-05-15 Kenneth G. Geles Anti-notch3 antibodies and antibody-drug conjugates
WO2014089177A2 (en) 2012-12-04 2014-06-12 Massachusetts Institute Of Technology Compounds, conjugates and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines
WO2014113729A2 (en) 2013-01-18 2014-07-24 Foundation Mecicine, Inc. Methods of treating cholangiocarcinoma
GB201302447D0 (en) 2013-02-12 2013-03-27 Oxford Biotherapeutics Ltd Therapeutic and diagnostic target
EP2961853B1 (en) 2013-02-28 2018-09-19 The Board of Regents of The University of Texas System Methods for classifying a cancer as susceptible to tmepai-directed therapies and treating such cancers
US9802987B2 (en) 2013-03-08 2017-10-31 Pfizer Inc. Immunogenic fusion polypeptides
RU2015142815A (ru) 2013-03-14 2017-04-12 Паркаш ГИЛЛ Лечение рака с использованием антител, связывающихся с поверхностным grp78
US10081673B2 (en) 2013-03-14 2018-09-25 Ffe Therapeutics Llc Compositions and methods for treating angiogenesis-related disorders
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
MX2015013163A (es) 2013-03-15 2016-04-04 Zyngenia Inc Complejos multiespecificos multivalente y monovalentes y sus usos.
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
EP3293275B1 (en) 2013-06-06 2021-08-04 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment prevention, and treatment of cancer using pd-l1 isoforms
US9587032B2 (en) 2013-06-12 2017-03-07 The Board Of Trustees Of The Leland Stanford Junior University IgE antibodies for the inhibition of tumor metastasis
US9428748B2 (en) 2013-06-17 2016-08-30 Hong Gao Method of expanding hematopoietic stem cells
US20160175401A1 (en) 2013-07-31 2016-06-23 Dana-Farber Cancer Institute Inc. Compoitions and methods for modulating thermogenesis using pth-related and egf-related compounds
US20160193308A1 (en) 2013-09-04 2016-07-07 Osaka University Dpp-4-targeting vaccine for treating diabetes
RU2662968C2 (ru) 2013-09-08 2018-07-31 Пфайзер Инк. Иммуногенная композиция против neisseria meningitidis (варианты)
EP3757130A1 (en) 2013-09-26 2020-12-30 Costim Pharmaceuticals Inc. Methods for treating hematologic cancers
AU2014337555C1 (en) 2013-10-15 2021-01-28 Seagen Inc. PEGylated drug-linkers for improved Ligand-Drug Conjugate pharmacokinetics
AU2014349828B2 (en) 2013-11-15 2021-01-28 Centre National De La Recherche Scientifique A molecular marker of Plasmodium falciparum artemisinin resistance
KR20160097294A (ko) 2013-12-09 2016-08-17 뉴욕 유니버시티 항-포도상구균 제제의 식세포 전달을 위한 조성물 및 방법
EP3083670A2 (en) 2013-12-17 2016-10-26 Westfälische Wilhelms-Universität Münster Means and methods for treating a pruritus-like skin-disease
PT3082878T (pt) 2013-12-19 2022-11-30 Seagen Inc Ligantes de carbamato de metileno para uso com conjugados de fármacos de marcação
EP2960252A1 (en) 2014-06-26 2015-12-30 Institut Pasteur Phospholipase for treatment of immunosuppression
EP4043493A1 (en) 2013-12-24 2022-08-17 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
US11014987B2 (en) 2013-12-24 2021-05-25 Janssen Pharmaceutics Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
US11421025B2 (en) 2013-12-27 2022-08-23 Osaka University Treatment of IL-17A diseases
ES2916722T3 (es) 2013-12-27 2022-07-05 Zymeworks Inc Sistemas de enlace que contienen sulfonamida para conjugados de fármacos
WO2015103026A2 (en) 2014-01-03 2015-07-09 The Regents Of The University Of Michigan Treatment of neurological disorders
AU2015206603B9 (en) 2014-01-14 2019-07-18 Dana-Farber Cancer Institute, Inc. Compositions and methods for identification, assessment, prevention, and treatment of melanoma using PD-L1 isoforms
CA2935423C (en) 2014-01-24 2023-11-07 Dana-Farber Cancer Institute, Inc. Antibody molecules to pd-1 and uses thereof
CA2937731C (en) 2014-01-27 2019-09-24 Pfizer Inc. Bifunctional cytotoxic agents
MX380864B (es) 2014-01-29 2025-03-12 Dana Farber Cancer Inst Inc Anticuerpos contra el dominio extracelular de muc1-c (muc1-c/ecd).
CA2938590C (en) 2014-02-11 2023-10-17 Visterra, Inc. Antibody molecules to dengue virus and uses thereof
WO2015123679A1 (en) 2014-02-17 2015-08-20 Seattle Genetics, Inc. Hydrophilic antibody-drug conjugates
EP3107567A4 (en) 2014-02-19 2017-10-25 Cangene Corporation Methods of modulating an immune response
WO2015138920A1 (en) 2014-03-14 2015-09-17 Novartis Ag Antibody molecules to lag-3 and uses thereof
EP4512889A3 (en) 2014-03-19 2025-05-07 Pfizer Inc. Method of cell culture
MX378397B (es) 2014-03-31 2025-03-10 Univ Johns Hopkins Uso de bacterias, productos bacterianos, y otras entidades inmunorreguladoras en combinacion con anticuerpos anti antigeno 4 de linfocitos t citotoxicos (ctla-4) y/o anti proteina 1 de muerte celular programada (pd-1) para tratar neoplasias de tumor solido.
CA3104268A1 (en) 2014-04-10 2015-10-15 Obi Pharma Inc. Antibodies, pharmaceutical compositions and uses thereof
EP3804745A1 (en) 2014-04-25 2021-04-14 The Brigham and Women's Hospital, Inc. Methods to manipulate alpha-fetoprotein (afp)
CA2946606C (en) 2014-05-13 2023-06-06 Bavarian Nordic A/S Combination therapy for treating cancer with a poxvirus expressing a tumor antigen and an antagonist of tim-3
EP3154585B1 (en) 2014-06-11 2022-02-23 Kathy A. Green Use of vista agonists and antagonists to suppress or enhance humoral immunity
EP3511413B1 (en) 2014-07-25 2022-09-07 Theravectys Lentiviral vectors for regulated expression of a chimeric antigen receptor molecule
WO2016016415A1 (en) 2014-07-31 2016-02-04 Amgen Research (Munich) Gmbh Bispecific single chain antibody construct with enhanced tissue distribution
UY36245A (es) 2014-07-31 2016-01-29 Amgen Res Munich Gmbh Constructos de anticuerpos para cdh19 y cd3
JP6749312B2 (ja) 2014-07-31 2020-09-02 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ 最適化された種間特異的二重特異性単鎖抗体コンストラクト
US10392444B2 (en) 2014-08-08 2019-08-27 Oncoquest, Inc. Tumor antigen specific antibodies and TLR3 stimulation to enhance the performance of checkpoint interference therapy of cancer
WO2016025202A1 (en) 2014-08-14 2016-02-18 The Regents Of The University Of Colorado Antibody-sirna conjugates and uses therefor
ES2808914T3 (es) 2014-09-04 2021-03-02 Stemcell Tech Inc Complejos de anticuerpo solubles para la activación y expansión de linfocitos T o células NK
WO2016040882A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of egfr inhibitors
KR20170068409A (ko) 2014-09-16 2017-06-19 이즈 참 리미티드 항-egfr 항체 및 그의 용도
EP3194421B1 (en) 2014-09-17 2021-11-03 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
KR20170066546A (ko) 2014-10-03 2017-06-14 노파르티스 아게 조합 요법
EP3204414B1 (en) 2014-10-07 2024-12-04 Ann and Robert H. Lurie Children's Hospital of Chicago Novel anti-nodal antibodies and methods of using same
WO2016061142A1 (en) 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
ES3013108T3 (en) 2014-11-05 2025-04-11 Annexon Inc Humanized anti-complement factor c1q antibodies and uses thereof
JP2018505911A (ja) 2014-12-05 2018-03-01 イミュネクスト，インコーポレーテッド 推定上のｖｉｓｔａ受容体としてのｖｓｉｇ８の同定と、ｖｉｓｔａ／ｖｓｉｇ８調節剤を産生するためのその使用
US11220545B2 (en) 2014-12-08 2022-01-11 Dana-Farber Cancer Institute, Inc. Methods for upregulating immune responses using combinations of anti-RGMb and anti-PD-1 agents
EP3233918A1 (en) 2014-12-19 2017-10-25 Novartis AG Combination therapies
JP2018504400A (ja) 2015-01-08 2018-02-15 バイオジェン・エムエイ・インコーポレイテッドＢｉｏｇｅｎ ＭＡ Ｉｎｃ． Ｌｉｎｇｏ‐１拮抗薬及び脱髄障害の治療のための使用
CA2973978A1 (en) 2015-01-14 2016-07-21 The Brigham And Women's Hospital, Inc. Treatment of cancer with anti-lap monoclonal antibodies
CN107405410B (zh) 2015-01-15 2021-08-10 OncoQuest制药有限公司 增加抗癌剂向靶递送的方法
WO2016124558A1 (en) 2015-02-03 2016-08-11 Ventana Medical Systems, Inc. Histochemical assay for evaluating expression of programmed death ligand 1 (pd-l1)
AU2016221318B2 (en) 2015-02-19 2020-06-25 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2016138312A2 (en) 2015-02-25 2016-09-01 Vanderbilt University Antibody-mediated neutralization of marburg virus
WO2016151432A1 (en) 2015-03-20 2016-09-29 Pfizer Inc. Bifunctional cytotoxic agents containing the cti pharmacophore
DK3283524T3 (da) 2015-04-17 2023-05-30 Amgen Res Munich Gmbh BISPECIFIKKE ANTISTOFKONSTRUKTIONER MOD CDH3 og CD3
WO2016170022A1 (en) 2015-04-21 2016-10-27 Institut Gustave Roussy Therapeutic methods, products and compositions inhibiting znf555
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
UY36751A (es) 2015-06-26 2017-01-31 Novartis Ag Anticuerpos de factor xi y métodos de uso
ES2878188T3 (es) 2015-07-29 2021-11-18 Novartis Ag Terapias de combinación que comprenden moléculas de anticuerpos contra LAG-3
WO2017019897A1 (en) 2015-07-29 2017-02-02 Novartis Ag Combination therapies comprising antibody molecules to tim-3
EP4378957A3 (en) 2015-07-29 2024-08-07 Novartis AG Combination therapies comprising antibody molecules to pd-1
EA039859B1 (ru) 2015-07-31 2022-03-21 Эмджен Рисерч (Мюник) Гмбх Биспецифические конструкты антител, связывающие egfrviii и cd3
TWI793062B (zh) 2015-07-31 2023-02-21 德商安美基研究（慕尼黑）公司 Ｄｌｌ３及ｃｄ３抗體構築體
TWI796283B (zh) 2015-07-31 2023-03-21 德商安美基研究（慕尼黑）公司 Ｍｓｌｎ及ｃｄ３抗體構築體
TWI829617B (zh) 2015-07-31 2024-01-21 德商安美基研究（慕尼黑）公司 Ｆｌｔ３及ｃｄ３抗體構築體
TWI744242B (zh) 2015-07-31 2021-11-01 德商安美基研究（慕尼黑）公司 Egfrviii及cd3抗體構築體
TWI717375B (zh) 2015-07-31 2021-02-01 德商安美基研究（慕尼黑）公司 Ｃｄ７０及ｃｄ３抗體構築體
EP3337822A1 (en) 2015-08-19 2018-06-27 Rutgers, The State University of New Jersey Novel methods of generating antibodies
HUE056769T2 (hu) 2015-09-04 2022-03-28 Primatope Therapeutics Inc Humanizált anti-CD40 antitestek és felhasználásuk
PT3922645T (pt) 2015-09-15 2025-05-29 Scholar Rock Inc ¿anticorpos anti-pró-miostatina/miostatina latente e suas utilizações
CA3214798A1 (en) 2015-09-23 2017-03-30 Pfizer Inc. Cells and method of cell culture
JP2018536628A (ja) 2015-10-07 2018-12-13 オービーアイ ファーマ インコーポレイテッド 新規炭水化物抗体、医薬組成物およびその使用
WO2017066561A2 (en) 2015-10-16 2017-04-20 President And Fellows Of Harvard College Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
EP3368157B1 (en) 2015-10-29 2022-06-29 Dana-Farber Cancer Institute, Inc. Methods for identification, assessment, prevention, and treatment of metabolic disorders using pm20d1 and n-lipidated amino acids
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
CN108350077A (zh) 2015-11-03 2018-07-31 糖模拟物有限公司 产生单克隆抗体、造血干细胞的方法和组合物以及利用所述抗体和造血干细胞的方法
JP6987068B2 (ja) 2015-11-09 2021-12-22 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia 癌マーカーおよび治療標的としてのグリピカン２
US11168131B2 (en) 2015-11-10 2021-11-09 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
DK3380522T5 (da) 2015-11-25 2024-09-30 Visterra Inc Antistofmolekyler til april og anvendelser deraf
TWI852735B (zh) 2015-12-04 2024-08-11 美商思進公司 四級胺化妥布賴森(tubulysin)化合物之結合物
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
RU2018125603A (ru) 2015-12-17 2020-01-21 Новартис Аг Комбинация ингибитора с-мет с молекулой антитела к pd-1 и ее применения
EP3389693A4 (en) 2015-12-18 2019-08-21 Agilvax, Inc. COMPOSITIONS AND METHODS RELATED TO XCT PEPTIDES
CN115814077A (zh) 2016-01-08 2023-03-21 供石公司 抗-原肌生长抑制素/潜伏肌生长抑制素抗体及其使用方法
WO2017134547A1 (en) 2016-02-01 2017-08-10 Pfizer Inc. Tubulysin analogs and methods for their preparation
SG11201805770UA (en) 2016-02-03 2018-08-30 Amgen Res Munich Gmbh BCMA and CD3 Bispecific T Cell Engaging Antibody Constructs
CA3011942A1 (en) 2016-02-03 2017-08-10 Amgen Research (Munich) Gmbh Psma and cd3 bispecific t cell engaging antibody constructs
WO2017134265A1 (en) 2016-02-05 2017-08-10 Institut Pasteur Use of inhibitors of adam12 as adjuvants in tumor therapies
TW202216201A (zh) 2016-02-12 2022-05-01 比利時商楊森製藥公司 抗vista抗體及片段、其用途及鑑定其之方法
WO2017139679A1 (en) 2016-02-12 2017-08-17 The Regents Of The University Of California Systems and compositions for diagnosing pathogenic fungal infection and methods of using the same
CA3017356A1 (en) 2016-03-10 2017-09-14 Aperisys, Inc. Antigen-binding fusion proteins with modified hsp70 domains
PL3365368T3 (pl) 2016-03-11 2023-08-21 Scholar Rock, Inc. Immunoglobuliny wiążące tgfbeta1 i ich zastosowanie
WO2017158421A1 (en) 2016-03-14 2017-09-21 University Of Oslo Anti-viral engineered immunoglobulins
MA43773B1 (fr) 2016-03-14 2026-01-30 Universitetet I Oslo Immunoglobulines génétiquement transformées ayant une liaison à fcrn altérée
US11186641B2 (en) 2016-03-17 2021-11-30 Oslo Universitetssykehus Hf Fusion proteins targeting tumour associated macrophages for treating cancer
JP7082604B2 (ja) 2016-03-21 2022-06-08 マレンゴ・セラピューティクス，インコーポレーテッド 多重特異性および多機能性分子ならびにその使用
KR102626498B1 (ko) 2016-03-25 2024-01-19 씨젠 인크. 페길화된 약물-링커 및 그의 중간체의 제조를 위한 공정
JP7155009B2 (ja) 2016-03-25 2022-10-18 ビステラ， インコーポレイテッド デングウイルスに対する抗体分子の製剤
CA3019753C (en) 2016-04-05 2021-10-26 Pfizer Inc. Cell culture process
CN109414489B (zh) 2016-04-08 2022-08-16 埃缇健康公司D/B/A泽尔拜尔 网蛋白-1结合抗体及其用途
WO2017181098A2 (en) 2016-04-15 2017-10-19 Visterra, Inc. Antibody molecules to zika virus and uses thereof
JP7184751B2 (ja) 2016-04-15 2022-12-06 イミュネクスト インコーポレイテッド 抗ヒトｖｉｓｔａ抗体およびその使用
JOP20170091B1 (ar) 2016-04-19 2021-08-17 Amgen Res Munich Gmbh إعطاء تركيبة ثنائية النوعية ترتبط بـ cd33 وcd3 للاستخدام في طريقة لعلاج اللوكيميا النخاعية
US10918627B2 (en) 2016-05-11 2021-02-16 Massachusetts Institute Of Technology Convergent and enantioselective total synthesis of Communesin analogs
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
US12071487B2 (en) 2016-06-17 2024-08-27 Life Technologies Corporation Site-specific crosslinking of antibodies
US11780924B2 (en) 2016-06-21 2023-10-10 University Of Oslo HLA binding vaccine moieties and uses thereof
US20200031924A1 (en) 2016-07-13 2020-01-30 Biogen Ma Inc. Dosage Regimens of Lingo-1 Antagonists and Uses for Treatment of Demyelinating Disorders
FI3494134T3 (fi) 2016-08-02 2026-02-19 Visterra Inc Muunneltuja polypeptidejä ja niiden käyttötapoja
EP3493853A1 (en) 2016-08-03 2019-06-12 Pfizer Inc Heteroaryl sulfone-based conjugation handles, methods for their preparation, and their use in synthesizing antibody drug conjugates
MX2019001302A (es) 2016-08-09 2019-06-12 Seattle Genetics Inc Conjugados de farmaco con enlazadores autoestabilizantes que tienen propiedades fisioquimicas mejoradas.
ES2919927T3 (es) 2016-08-10 2022-07-29 Pasteur Institut Métodos y reactivos para la detección del paludismo por Plasmodium falciparum resistente a la piperaquina
RS64541B1 (sr) 2016-08-15 2023-09-29 Novartis Ag Režimi i postupci za lečenje multiple skleroze upotrebom ofatumumaba
CN109906232B (zh) 2016-09-23 2023-11-07 马伦戈治疗公司 包含λ轻链和κ轻链的多特异性抗体分子
EP3515494B1 (en) 2016-09-26 2026-02-25 The Brigham and Women's Hospital, Inc. Regulators of b cell-mediated immunosuppression
MX2019003727A (es) 2016-09-29 2019-08-05 Amgen Inc Proteinas de union a antigeno de baja viscosidad y metodos de prepararlas.
CN109843334A (zh) 2016-10-18 2019-06-04 西雅图基因公司 烟酰胺腺嘌呤二核苷酸补救途径抑制剂的靶向递送
CN118047864A (zh) 2016-12-23 2024-05-17 百时美施贵宝公司 用于改进生物分析和生物加工特性的治疗性免疫球蛋白g4的设计
BR112019012667A2 (pt) 2016-12-23 2020-02-11 Novartis Ag Anticorpos do fator xi e métodos de uso
RU2019123063A (ru) 2016-12-23 2021-01-26 Вистерра, Инк. Связывающие полипептиды и способы их получения
US11155611B2 (en) 2017-01-06 2021-10-26 Scholar Rock, Inc. Compositions and methods for making and using anti-myostatin antibodies
WO2018129329A1 (en) 2017-01-06 2018-07-12 Scholar Rock, Inc. ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF
PT3565592T (pt) 2017-01-06 2023-05-31 Scholar Rock Inc Tratamento de doenças metabólicas através da inibição da ativação da miostatina
ES2994374T3 (en) 2017-01-18 2025-01-23 Visterra Inc Antibody molecule-drug conjugates and uses thereof
WO2018138591A1 (en) 2017-01-24 2018-08-02 Pfizer Inc. Calicheamicin derivatives and antibody drug conjugates thereof
US10183070B2 (en) 2017-01-31 2019-01-22 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
AU2018214223B2 (en) 2017-02-02 2025-08-14 Amgen Inc. Low pH pharmaceutical composition comprising T cell engaging antibody constructs
US20180221476A1 (en) 2017-02-06 2018-08-09 Oncoquest Nc. Treatment of cancer with therapeutic monoclonal antibody specific for a tumor associated antigen and an immune adjuvant
WO2018151820A1 (en) 2017-02-16 2018-08-23 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN110382529B (zh) 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
WO2018165649A1 (en) 2017-03-10 2018-09-13 Embera Neurotherapeutics, Inc. Pharmaceutical compositions and uses thereof
US20200056190A1 (en) 2017-03-16 2020-02-20 Pfizer Inc. Tyrosine prototrophy
WO2018176019A1 (en) 2017-03-24 2018-09-27 The Regents Of The University Of California Proteoglycan irregularities in abnormal fibroblasts and therapies based therefrom
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
KR20200020662A (ko) 2017-04-03 2020-02-26 온콜로지, 인크. 면역-종양학 제제와 함께 ps-표적화 항체를 사용하여 암을 치료하는 방법
EP3607320A4 (en) 2017-04-03 2021-04-21 The Regents of the University of California COMPOSITIONS AND METHODS OF DIAGNOSING Pancreatic Cancer
JP2020517256A (ja) 2017-04-19 2020-06-18 エルスター セラピューティクス， インコーポレイテッド 多重特異性分子およびその使用
US11203629B2 (en) 2017-04-22 2021-12-21 Immunomic Therapeutics, Inc. LAMP constructs
WO2018201087A1 (en) 2017-04-27 2018-11-01 Seattle Genetics, Inc. Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates
WO2018200533A1 (en) 2017-04-28 2018-11-01 Amgen Inc. Excipients to reduce the viscosity of antibody formulations and formulation compositions
US20200179511A1 (en) 2017-04-28 2020-06-11 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
EP4328241A3 (en) 2017-04-28 2024-06-05 Marengo Therapeutics, Inc. Multispecific molecules comprising a non-immunoglobulin heterodimerization domain and uses thereof
CA3061950A1 (en) 2017-05-02 2018-11-08 Immunomic Therapeutics, Inc. Lamp (lysosomal associated membrane protein) constructs comprising cancer antigens
KR102700015B1 (ko) 2017-05-05 2024-08-29 암젠 인크 개선된 저장 및 투여를 위한 이중특이적 항체 구축물을 포함하는 약제학적 조성물
EP3630830A1 (en) 2017-05-23 2020-04-08 Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) Novel cd73 antibody, preparation and uses thereof
WO2018222901A1 (en) 2017-05-31 2018-12-06 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
US11312783B2 (en) 2017-06-22 2022-04-26 Novartis Ag Antibody molecules to CD73 and uses thereof
WO2018237173A1 (en) 2017-06-22 2018-12-27 Novartis Ag ANTIBODY MOLECULES DIRECTED AGAINST CD73 AND CORRESPONDING USES
US20200223924A1 (en) 2017-06-27 2020-07-16 Novartis Ag Dosage regimens for anti-tim-3 antibodies and uses thereof
EP3431496A1 (en) 2017-07-19 2019-01-23 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti- isoasp7 amyloid beta antibodies and uses thereof
KR20200031659A (ko) 2017-07-20 2020-03-24 노파르티스 아게 항-lag-3 항체의 투여 요법 및 그의 용도
US12358992B2 (en) 2017-07-28 2025-07-15 Scholar Rock, Inc. LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
KR20250093620A (ko) 2017-09-15 2025-06-24 암젠 인크 치료 단백질의 동결건조된 약학적 제형을 위한 방법
JP2020533983A (ja) 2017-09-15 2020-11-26 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 目的のポリペプチドのラージスケールの製造間のオンラインバイオマス静電容量モニタリング
MY205689A (en) 2017-10-02 2024-11-06 Visterra Inc Antibody molecules to cd138 and uses thereof
ES2759622T3 (es) 2017-10-02 2020-05-11 Certest Biotec S L Anticuerpos anti-Dps y dispositivos de prueba para la detección de bacterias del género Campylobacter
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
MX2020004074A (es) 2017-10-19 2020-10-16 Debiopharm Int Sa Producto de combinacion para el tratamiento de cancer.
US20200283485A1 (en) 2017-10-20 2020-09-10 Institut Curie Hook fusion protein for regulating the cellular trafficking of a target protein
EP3697809A1 (en) 2017-10-20 2020-08-26 Institut Curie Dap10/12 based cars adapted for rush
US11591385B2 (en) 2017-11-09 2023-02-28 Pinteon Therapeutics Inc. Methods and compositions for the generation and use of humanized conformation-specific phosphorylated tau antibodies
CN111655288A (zh) 2017-11-16 2020-09-11 诺华股份有限公司 组合疗法
EP3720881A1 (en) 2017-12-08 2020-10-14 Elstar Therapeutics, Inc. Multispecific molecules and uses thereof
TWI827570B (zh) 2017-12-11 2024-01-01 美商安進公司 雙特異性抗體產品之連續製造製程
UY38041A (es) 2017-12-29 2019-06-28 Amgen Inc Construcción de anticuerpo biespecífico dirigida a muc17 y cd3
WO2019139987A1 (en) 2018-01-09 2019-07-18 Elstar Therapeutics, Inc. Calreticulin binding constructs and engineered t cells for the treatment of diseases
EP3743101A2 (en) 2018-01-25 2020-12-02 ACM Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated antigen as well as methods of making and uses thereof
WO2019150309A1 (en) 2018-02-02 2019-08-08 Hammack Scott Modulators of gpr68 and uses thereof for treating and preventing diseases
US11857565B2 (en) 2018-02-20 2024-01-02 Seagen Inc. Hydrophobic Auristatin F compounds and conjugates thereof
WO2019164891A1 (en) 2018-02-21 2019-08-29 Celgene Corporation Bcma-binding antibodies and uses thereof
EP3530282A1 (en) 2018-02-27 2019-08-28 Diaccurate Therapeutic methods
CA3090305A1 (en) 2018-02-28 2019-09-06 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-btnl2 and immune checkpoint blockade agents
CA3093838A1 (en) 2018-03-14 2019-09-19 Memorial Sloan Kettering Cancer Center Anti-polysialic acid antibodies and uses thereof
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
US12152073B2 (en) 2018-03-14 2024-11-26 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN111902160B (zh) 2018-03-16 2025-05-09 百时美施贵宝公司 蛋白质生产期间的代谢酶活性和二硫键还原
EP4253958A3 (en) 2018-03-26 2023-12-06 Glycanostics s.r.o. Means and methods for glycoprofiling of a protein
US12103972B2 (en) 2018-04-06 2024-10-01 Dana-Farber Cancer Institute, Inc. KIR3DL3 as an HHLA2 receptor, anti-HHLA2 antibodies, and uses thereof
US20210147547A1 (en) 2018-04-13 2021-05-20 Novartis Ag Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
CN111886023B (zh) 2018-04-24 2024-09-27 安源医药科技（上海）有限公司 针对tim-3的抗体及其用途
EP3793595A1 (en) 2018-05-15 2021-03-24 Immunomic Therapeutics, Inc. Improved lamp constructs comprising allergens
UY38247A (es) 2018-05-30 2019-12-31 Novartis Ag Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
US20210214459A1 (en) 2018-05-31 2021-07-15 Novartis Ag Antibody molecules to cd73 and uses thereof
AU2019277029C1 (en) 2018-06-01 2024-01-04 Novartis Ag Binding molecules against BCMA and uses thereof
AU2019282264A1 (en) 2018-06-05 2020-11-26 Amgen Inc. Modulating antibody dependent cellular phagocytosis
TWI851577B (zh) 2018-06-07 2024-08-11 美商思進公司 喜樹鹼結合物
KR20210035173A (ko) 2018-06-19 2021-03-31 아타르가, 엘엘씨 보체 성분 5에 대한 항체분자 및 이의 용도
TW202016144A (zh) 2018-06-21 2020-05-01 日商第一三共股份有限公司 包括cd3抗原結合片段之組成物及其用途
WO2020010250A2 (en) 2018-07-03 2020-01-09 Elstar Therapeutics, Inc. Anti-tcr antibody molecules and uses thereof
WO2020008083A1 (es) 2018-07-05 2020-01-09 Consejo Superior De Investigaciones Científicas Diana terapéutica en receptores de quimiocinas para la selección de compuestos útiles para el tratamiento de procesos patológicos que implican la señalización de quimiocinas
US12252531B2 (en) 2018-07-11 2025-03-18 Scholar Rock, Inc. Methods of screening for high-affinity, isoform-selective TGFβ1 inhibitors
HRP20212034T1 (hr) 2018-07-11 2022-04-01 Scholar Rock, Inc. Izoformno selektivni inhibitori tgfbeta1 i njihove uporabe
US20210340238A1 (en) 2018-07-11 2021-11-04 Scholar Rock, Inc. TGFß1 INHIBITORS AND USE THEREOF
JP2021531306A (ja) 2018-07-25 2021-11-18 アドバンスド アクセラレーター アプリケーションズ エスエー 神経内分泌腫瘍の処置の方法
CA3107186A1 (en) 2018-07-30 2020-02-06 Amgen Research (Munich) Gmbh Prolonged administration of a bispecific antibody construct binding to cd33 and cd3
WO2020025792A1 (en) 2018-08-03 2020-02-06 Amgen Research (Munich) Gmbh Antibody constructs for cldn18.2 and cd3
RS65658B1 (sr) 2018-08-27 2024-07-31 Affimed Gmbh Kriokonzervirane nk ćelije prethodno punjene konstruktom antitela
AU2019339895A1 (en) 2018-09-11 2021-03-11 Amgen Inc. Methods of modulating antibody-dependent cell-mediated cytotoxicity
WO2020053808A1 (en) 2018-09-12 2020-03-19 Georg Dewald Method of diagnosing vasoregulatory disorders
CN112996539A (zh) 2018-09-12 2021-06-18 Acm生物实验室私人有限公司 包含共价结合的抗原的聚合物囊泡以及其制备方法和用途
CN113164777B (zh) 2018-09-27 2024-12-13 马伦戈治疗公司 Csf1r/ccr2多特异性抗体
AR116548A1 (es) 2018-09-28 2021-05-19 Amgen Inc Anticuerpos contra bcma soluble
EP3860641A1 (en) 2018-10-05 2021-08-11 Bavarian Nordic A/S Combination therapy for treating cancer with an intravenous administration of a recombinant mva and an immune checkpoint antagonist or agonist
AR117650A1 (es) 2018-10-11 2021-08-18 Amgen Inc Procesamiento posterior de constructos de anticuerpos biespecíficos
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
BR112021007765A2 (pt) 2018-10-23 2021-08-03 Scholar Rock, Inc. inibidores seletivos de rgmc e uso dos mesmos
US12227548B2 (en) 2018-11-19 2025-02-18 Dana-Farber Cancer Institute, Inc. Use of IRE1α-XBP1 signaling pathway biomarkers for modulating immune responses
CN113056284A (zh) 2018-11-20 2021-06-29 巴法里安诺迪克有限公司 通过肿瘤内和/或静脉内施用编码4-1bbl(cd137l)和/或cd40l的重组mva治疗癌症的疗法
JP2022513702A (ja) 2018-12-06 2022-02-09 ファイザー・インク 阻害剤産生が低下した細胞およびその使用方法
JP2022514280A (ja) 2018-12-20 2022-02-10 ノバルティス アーゲー Ｍｄｍ２阻害剤のための延長低用量レジメン
PH12021551860A1 (en) 2019-01-30 2022-05-16 Scholar Rock Inc Ltbp complex-specific inhibitors of tgf㟠and uses thereof
US12241061B2 (en) 2019-02-04 2025-03-04 National University Corporation Ehime University CAR library and scFv manufacturing method
EP3693063A1 (en) 2019-02-06 2020-08-12 Diaccurate Methods and compositions for treating cancer
US20220128578A1 (en) 2019-02-12 2022-04-28 Biogen Ma Inc. Biomarkers of progressive multifocal leukoencephalopathy
CN117679532A (zh) 2019-02-15 2024-03-12 上海药明合联生物技术有限公司 用于制备具有改善的同质性的抗体-药物缀合物的方法
US10871640B2 (en) 2019-02-15 2020-12-22 Perkinelmer Cellular Technologies Germany Gmbh Methods and systems for automated imaging of three-dimensional objects
US11254736B2 (en) 2019-02-15 2022-02-22 Integral Molecular, Inc. Antibodies comprising a common light chain and uses thereof
US12109273B2 (en) 2019-02-15 2024-10-08 Wuxi Xdc Singapore Private Limited Process for preparing antibody-drug conjugates with improved homogeneity
MA54955A (fr) 2019-02-15 2021-12-22 Integral Molecular Inc Anticorps anti-claudine 6 et leurs utilisations
EP3927745A1 (en) 2019-02-21 2021-12-29 Marengo Therapeutics, Inc. Multifunctional molecules that bind to t cells and uses thereof to treat autoimmune disorders
AU2020226904B2 (en) 2019-02-21 2025-05-01 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
AU2020226893B2 (en) 2019-02-21 2025-02-27 Marengo Therapeutics, Inc. Multifunctional molecules that bind to T cell related cancer cells and uses thereof
JP7706373B2 (ja) 2019-02-21 2025-07-11 マレンゴ・セラピューティクス，インコーポレーテッド カルレティキュリンに結合する多機能性分子およびその使用
GB2597851B (en) 2019-02-21 2024-05-29 Marengo Therapeutics Inc Antibody molecules that bind to NKP30 and uses thereof
KR20210152472A (ko) 2019-03-11 2021-12-15 메모리얼 슬로안 케터링 캔서 센터 Cd22 항체 및 이를 사용하는 방법
JP2022527790A (ja) 2019-03-29 2022-06-06 アターガ，エルエルシー 抗ｆｇｆ２３抗体分子
US20220289854A1 (en) 2019-04-30 2022-09-15 Dana-Farber Cancer Institute, Inc. Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
CA3139809A1 (en) 2019-05-10 2020-11-19 Takeda Pharmaceutical Company Limited Antibody drug conjugates
WO2020236797A1 (en) 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2020290573B2 (en) 2019-06-13 2026-01-29 Amgen Inc. Automated biomass-based perfusion control in the manufacturing of biologics
CA3142021A1 (en) 2019-06-17 2020-12-24 Visterra, Inc. Humanized antibody molecules to cd138 and uses thereof
US20220257653A1 (en) 2019-07-19 2022-08-18 The Children's Hospital Of Philadelphia Chimeric antigen receptors containing glypican 2 binding domains
PH12022550165A1 (en) 2019-07-26 2023-05-08 Visterra Inc Interleukin-2 agents and uses thereof
WO2021023860A1 (en) 2019-08-07 2021-02-11 Db Biotech, As Improved horseradish peroxidase polypeptides
WO2021042066A1 (en) 2019-08-30 2021-03-04 Foundation Medicine, Inc. Kmt2a-maml2 fusion molecules and uses thereof
EP4025303A1 (en) 2019-09-04 2022-07-13 Deutsches Zentrum für Neurodegenerative Erkrankungen e.V. (DZNE) Herv inhibitors for use in treating tauopathies
US20220306741A1 (en) 2019-09-10 2022-09-29 Amgen Inc. Purification Method for Bispecific antigen-binding Polypeptides with Enhanced Protein L Capture Dynamic Binding Capacity
JP2022548881A (ja) 2019-09-18 2022-11-22 ノバルティス アーゲー Ｅｎｔｐｄ２抗体、組合せ療法並びに抗体及び組合せ療法を使用する方法
TW202124446A (zh) 2019-09-18 2021-07-01 瑞士商諾華公司 與ｅｎｔｐｄ２抗體之組合療法
WO2021055865A1 (en) 2019-09-19 2021-03-25 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
EP4034157A1 (en) 2019-09-27 2022-08-03 Pfizer Inc. Neisseria meningitidis compositions and methods thereof
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
KR20220079606A (ko) 2019-10-04 2022-06-13 씨젠 인크. 캄프토테신 펩티드 접합체
JP2022551732A (ja) 2019-10-18 2022-12-13 イミュノミック セラピューティックス， インコーポレイテッド がん抗原を含む改良ｌａｍｐ構築物
CA3158298A1 (en) 2019-10-21 2021-04-29 Novartis Ag Combination therapies with venetoclax and tim-3 inhibitors
TW202128191A (zh) 2019-10-21 2021-08-01 瑞士商諾華公司 Tim-3抑制劑及其用途
CA3156683A1 (en) 2019-11-13 2021-05-20 Amgen Inc. Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
CN114867491B (zh) 2019-11-20 2025-08-15 巴法里安诺迪克有限公司 用于肿瘤内和/或静脉内施用以治疗癌症的重组mva病毒
KR20220116257A (ko) 2019-12-20 2022-08-22 노파르티스 아게 골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
JP2023507323A (ja) 2019-12-20 2023-02-22 アムジエン・インコーポレーテツド 固形腫瘍の治療のためのメソセリン標的化ｃｄ４０アゴニスト多重特異性抗体コンストラクト
AU2020414409A1 (en) 2019-12-27 2022-06-16 Affimed Gmbh Method for the production of bispecific FcyRIIl x CD30 antibody construct
TWI877278B (zh) 2019-12-30 2025-03-21 美商思進公司 以非海藻糖苷化抗－ｃｄ７０抗體治療癌症之方法
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
AU2020416273A1 (en) 2020-01-03 2022-07-28 Marengo Therapeutics, Inc. Anti-TCR antibody molecules and uses thereof
CA3167427A1 (en) 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
AU2021205440A1 (en) 2020-01-11 2022-09-01 Scholar Rock,Inc. TGF-beta inhibitors and use thereof
TWI869528B (zh) 2020-01-13 2025-01-11 美商威特拉公司 C5ar1抗體分子及其用途
US20230058489A1 (en) 2020-01-17 2023-02-23 Novartis Ag Combination comprising a tim-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
WO2021150824A1 (en) 2020-01-22 2021-07-29 Amgen Research (Munich) Gmbh Combinations of antibody constructs and inhibitors of cytokine release syndrome and uses thereof
BR112022017064A2 (pt) 2020-02-25 2022-11-16 Mediboston Inc Derivados da camptotecina e seus conjugados
EP4118113A1 (en) 2020-03-12 2023-01-18 Amgen Inc. Method for treatment and prophylaxis of crs in patients comprising a combination of bispecifc antibodies binding to cds x cancer cell and tnfalpha or il-6 inhibitor
MX2022011632A (es) 2020-03-19 2022-10-13 Amgen Inc Anticuerpos contra mucina 17 y usos de los mismos.
US11815513B2 (en) 2020-04-01 2023-11-14 Institut Pasteur Severe acute respiratory syndrome (SARS)-associated coronavirus diagnostics
US12326451B2 (en) 2020-04-01 2025-06-10 Institut Pasteur Severe acute respiratory syndrome (SARS)—associated coronavirus diagnostics
EP4126064A1 (en) 2020-04-03 2023-02-08 Visterra, Inc. Antibody molecule-drug conjugates and uses thereof
BR112022020332A2 (pt) 2020-04-10 2022-12-13 Seagen Inc Composto conjugado anticorpo-droga, composição, método de tratamento de câncer e de um distúrbio autoimune
WO2021209824A1 (en) 2020-04-17 2021-10-21 Institut Pasteur Methods and products for serological analysis of sars-cov-2 infection
US20230242647A1 (en) 2020-05-01 2023-08-03 Novartis Ag Engineered immunoglobulins
US20230167193A1 (en) 2020-05-01 2023-06-01 Novartis Ag Immunoglobulin variants
US12312412B2 (en) 2020-05-19 2025-05-27 Amgen Inc. MAGEB2 binding constructs
WO2021239666A1 (en) 2020-05-26 2021-12-02 Diaccurate Therapeutic methods
AU2021281554A1 (en) 2020-05-29 2022-12-15 Amgen Inc. Adverse effects-mitigating administration of a bispecific antibody construct binding to CD33 and CD3
US20230235080A1 (en) 2020-06-03 2023-07-27 Bionecure Therapeutics, Inc. Trophoblast cell-surface antigen-2 (trop-2) antibodies
CA3187823A1 (en) 2020-06-24 2021-12-30 Visterra, Inc. Antibody molecules to april and uses thereof
US20230256114A1 (en) 2020-07-07 2023-08-17 Bionecure Therapeutics, Inc. Novel maytansinoids as adc payloads and their use for the treatment of cancer
CA3184852A1 (en) 2020-07-10 2022-01-13 Lida Katsimpardi Use of gdf11 to diagnose and treat anxiety and depression
EP4183416A4 (en) 2020-07-17 2025-08-27 Mitsubishi Tanabe Pharma Corp AGENT FOR PREVENTING OR TREATING MUSCULAR DISEASE
WO2022026592A2 (en) 2020-07-28 2022-02-03 Celltas Bio, Inc. Antibody molecules to coronavirus and uses thereof
US12247978B2 (en) 2020-08-05 2025-03-11 Arizona Board Of Regents On Behalf Of Northern Arizona University Compositions and methods for detection and treatment of coronavirus infection
GB2616354A (en) 2020-08-26 2023-09-06 Marengo Therapeutics Inc Methods of detecting TRBC1 or TRBC2
KR20230074144A (ko) 2020-08-26 2023-05-26 마렝고 테라퓨틱스, 인크. NKp30에 결합하는 항체 분자 및 이의 용도
CN116249718A (zh) 2020-08-26 2023-06-09 马伦戈治疗公司 结合至钙网蛋白的多功能性分子及其用途
EP4204020A1 (en) 2020-08-31 2023-07-05 Advanced Accelerator Applications International S.A. Method of treating psma-expressing cancers
WO2022043557A1 (en) 2020-08-31 2022-03-03 Advanced Accelerator Applications International Sa Method of treating psma-expressing cancers
IL300917A (en) 2020-09-04 2023-04-01 Univ Rutgers Sars-cov-2 vaccines and antibodies
WO2022058621A1 (en) 2020-09-21 2022-03-24 Theravectys High throughput methods and products for sars-cov-2 sero-neutralization assay
CN116368154A (zh) 2020-10-08 2023-06-30 阿菲姆德股份有限公司 三特异性结合剂
EP4229081A1 (en) 2020-10-15 2023-08-23 The United States of America, as represented by The Secretary, Department of Health and Human Services Antibody specific for sars-cov-2 receptor binding domain and therapeutic methods
WO2022087274A1 (en) 2020-10-21 2022-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibodies that neutralize type-i interferon (ifn) activity
EP4232062A4 (en) 2020-10-23 2024-09-11 HAN, Hq BIFUNCTIONAL ANTAGONISTS OF ACTIVIN AND TUMOR NECROSIS FACTOR ALPHA AND THEIR USES
AU2021374083A1 (en) 2020-11-06 2023-06-01 Novartis Ag Anti-cd19 agent and b cell targeting agent combination therapy for treating b cell malignancies
MX2023005323A (es) 2020-11-06 2023-05-19 Amgen Inc Construcciones polipeptidicas que se unen a cd3.
AU2021374036A1 (en) 2020-11-06 2023-06-08 Amgen Inc. Polypeptide constructs selectively binding to cldn6 and cd3
EP4240491A1 (en) 2020-11-06 2023-09-13 Novartis AG Cd19 binding molecules and uses thereof
CA3200317A1 (en) 2020-11-06 2022-05-12 Amgen Inc. Multitargeting bispecific antigen-binding molecules of increased selectivity
KR20230098335A (ko) 2020-11-06 2023-07-03 암젠 인크 클리핑 비율이 감소된 항원 결합 도메인
MX2023005381A (es) 2020-11-09 2023-05-23 Takeda Pharmaceuticals Co Conjugados de anticuerpo y farmaco.
AU2021391924A1 (en) 2020-12-04 2023-06-22 The General Hospital Corporation Methods of using interleukin-2 agents
JP2024504912A (ja) 2020-12-30 2024-02-02 イミュノミック セラピューティックス， インコーポレイテッド 抗ｈｖｅｍ抗体
WO2022153195A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Anti-dll3 antibody-drug conjugate
WO2022153194A1 (en) 2021-01-13 2022-07-21 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
WO2022155518A1 (en) 2021-01-15 2022-07-21 Seagen Inc. Immunomodulatory antibody-drug conjugates
US20250282870A1 (en) 2021-01-20 2025-09-11 Bioentre Llc Ctla4-binding proteins and methods of treating cancer
AU2022211021A1 (en) 2021-01-20 2023-08-03 Visterra, Inc. Interleukin-2 mutants and uses thereof
EP4284510A1 (en) 2021-01-29 2023-12-06 Novartis AG Dosage regimes for anti-cd73 and anti-entpd2 antibodies and uses thereof
MX2023009113A (es) 2021-02-03 2023-08-10 Seagen Inc Conjugados y compuestos inmunoestimulantes.
US20240230671A9 (en) 2021-02-24 2024-07-11 Alladapt Immunotherapeutics, Inc. Compositions and methods for identification of cross-reactive allergenic proteins and treatment of allergies
US12521444B2 (en) 2021-02-25 2026-01-13 Fortvita Biologics Limited Anti-HER2 antibody-drug conjugates and uses thereof
CN117321418A (zh) 2021-03-18 2023-12-29 诺华股份有限公司 癌症生物标志物及其使用方法
IL305886A (en) 2021-03-18 2023-11-01 Seagen Inc Selective release of drugs from internalized conjugates of biologically active compounds
CA3213636A1 (en) 2021-03-18 2022-09-22 Seagen Inc. Selective drug release from internalized conjugates of biologically active compounds
WO2022204581A2 (en) 2021-03-26 2022-09-29 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
AR125290A1 (es) 2021-04-02 2023-07-05 Amgen Inc Construcciones de unión a mageb2
TW202304979A (zh) 2021-04-07 2023-02-01 瑞士商諾華公司 抗ＴＧＦβ抗體及其他治療劑用於治療增殖性疾病之用途
JP2024515591A (ja) 2021-04-08 2024-04-10 マレンゴ・セラピューティクス，インコーポレーテッド Ｔｃｒに結合する多機能性分子およびその使用
WO2022218957A1 (en) 2021-04-12 2022-10-20 Acm Biolabs Pte Ltd Polymersomes comprising a soluble encapsulated polynucleotide and an ionizable lipid as well as methods of making and uses thereof
WO2022234102A1 (en) 2021-05-06 2022-11-10 Amgen Research (Munich) Gmbh Cd20 and cd22 targeting antigen-binding molecules for use in proliferative diseases
IL308795A (en) 2021-05-28 2024-01-01 Seagen Inc Anthracycline antibody conjugates
WO2022256723A2 (en) 2021-06-03 2022-12-08 Scholar Rock, Inc. Tgf-beta inhibitors and therapeutic use thereof
JP2024524159A (ja) 2021-06-23 2024-07-05 スカラー ロック インコーポレイテッド 代謝障害の治療における使用のためのｇｌｐ－１経路活性化剤と組み合わせたミオスタチン経路阻害剤
EP4362977A1 (en) 2021-06-29 2024-05-08 Seagen Inc. Methods of treating cancer with a combination of a nonfucosylated anti-cd70 antibody and a cd47 antagonist
AU2022310862A1 (en) 2021-07-14 2024-02-01 Regeneron Pharmaceuticals, Inc. Engineered t cell receptors fused to binding domains from antibodies
AU2022320948A1 (en) 2021-07-30 2024-01-18 Affimed Gmbh Duplexbodies
CA3228822A1 (en) 2021-08-26 2023-03-02 Jan Tkac Glycoprotein biomarkers for diagnosing cancer
US20240385193A1 (en) 2021-09-14 2024-11-21 Glycanostics S.R.O. Use of lectins to determine mammaglobin-a glycoforms in breast cancer
EP4405396A2 (en) 2021-09-20 2024-07-31 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
CA3231484A1 (en) 2021-10-01 2023-04-06 Qinwen Mao Pathologic tdp-43 as a biomarker for the diagnosis of tdp-43 proteinopathy
AU2022381918A1 (en) 2021-11-03 2024-06-13 Affimed Gmbh Bispecific cd16a binders
JP2024543822A (ja) 2021-11-03 2024-11-26 アフィメド ゲーエムベーハー 二重特異性ｃｄ１６ａバインダー
WO2023079058A1 (en) 2021-11-05 2023-05-11 Yokogawa Insilico Biotechnology Gmbh Cell culture with reduced production of lactate
US20250034559A1 (en) 2021-11-17 2025-01-30 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023097254A1 (en) 2021-11-24 2023-06-01 Visterra, Inc. Engineered antibody molecules to cd138 and uses thereof
CN120131911A (zh) 2021-12-01 2025-06-13 威特拉公司 使用白细胞介素-2药剂的方法
EP4452305A1 (en) 2021-12-23 2024-10-30 Bavarian Nordic A/S Recombinant mva viruses for intraperitoneal administration for treating cancer
KR20240139082A (ko) 2022-02-02 2024-09-20 화이자 인코포레이티드 시스테인 프로토트로피
TW202342548A (zh) 2022-02-07 2023-11-01 美商威特拉公司 抗獨特型(anti-idiotype)抗體分子及其用途
IL315508A (en) 2022-03-17 2024-11-01 Seagen Inc Camptothecin conjugates
CA3247515A1 (en) 2022-04-10 2023-10-19 Immunomic Therapeutics, Inc. Bicistronic lamp constructions comprising genes that enhance the immune response and methods of their use
US20240092921A1 (en) 2022-04-25 2024-03-21 Visterra, Inc. Antibody molecules to april and uses thereof
CA3252067A1 (en) 2022-05-06 2023-11-09 Seagen Inc. Immunomodulatory Antibody-Drug Conjugates
IL316597A (en) 2022-05-12 2024-12-01 Amgen Res Munich Gmbh Multi-chain, multi-purpose, bispecific antigen-binding compounds with enhanced sensitivity
EP4522757A2 (en) 2022-05-13 2025-03-19 Voyager Therapeutics, Inc. Compositions and methods for the treatment of her2 positive cancer
EP4526478A1 (en) 2022-05-18 2025-03-26 Institut Pasteur Identification of a human circovirus
US20260053913A1 (en) 2022-06-10 2026-02-26 Bioentre Llc Combinations of ctla4 binding proteins and methods of treating cancer
EP4296279A1 (en) 2022-06-23 2023-12-27 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Anti-transthyretin (ttr) binding proteins and uses thereof
JP2025524986A (ja) 2022-07-27 2025-08-01 メディボストン リミテッド オーリスタチン誘導体およびそのコンジュゲート
AU2023320054A1 (en) 2022-08-03 2025-02-06 Regents Of The University Of Minnesota Immunostimulatory anti-pd-l1-drug conjugates
JP2025528068A (ja) 2022-08-03 2025-08-26 ボイジャー セラピューティクス インコーポレイテッド 血液脳関門を通過させるための組成物及び方法
EP4321522A1 (en) 2022-08-12 2024-02-14 Seagen Inc. Cytotoxic compounds and conjugates thereof
JP2025533434A (ja) 2022-09-14 2025-10-07 アムジエン・インコーポレーテツド 二重特異性分子安定化組成物
EP4626933A1 (en) 2022-11-30 2025-10-08 Integral Molecular, Inc. Antibodies directed to claudin 6, including bispecific formats thereof
WO2024129756A1 (en) 2022-12-13 2024-06-20 Seagen Inc. Site-specific engineered cysteine antibody drug conjugates
AU2023413166A1 (en) 2022-12-22 2025-07-03 Scholar Rock, Inc. Selective and potent inhibitory antibodies of myostatin activation
WO2024168061A2 (en) 2023-02-07 2024-08-15 Ayan Therapeutics Inc. Antibody molecules binding to sars-cov-2
WO2024187062A1 (en) 2023-03-08 2024-09-12 Amgen Inc. Controlled-ice nucleation lyophilization process for bispecific molecules
EP4698631A1 (en) 2023-04-21 2026-02-25 Pfizer Inc. Improved cells and cell cultures
MX2025014635A (es) 2023-06-14 2026-02-03 Amgen Inc Moleculas captadoras de enmascaramiento de celulas t
WO2025054181A1 (en) 2023-09-05 2025-03-13 Seagen Inc. Targeted degrader molecules and ligand drug conjugates thereof
WO2025090774A1 (en) 2023-10-24 2025-05-01 Seagen Inc. Chemotherapeutic compounds and methods of use
WO2025122634A1 (en) 2023-12-05 2025-06-12 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2025149947A1 (en) 2024-01-12 2025-07-17 Seagen Inc. Antibody-drug conjugates
WO2025155971A1 (en) 2024-01-19 2025-07-24 Immunomic Therapeutics, Inc Anti-activin receptor 1c (alk-7) receptor antibodies
WO2025193454A1 (en) 2024-03-01 2025-09-18 Prelude Therapeutics Incorporated Brm and brg1 targeting antibody-drug conjugates and methods of use thereof
WO2025210195A1 (en) 2024-04-03 2025-10-09 Institut Pasteur Apsab combines a nuclease/helicase protein and an argonaute-like protein to cleave dna
WO2025233675A1 (en) 2024-05-10 2025-11-13 Institut Pasteur Use of talosaminidase to regulate populations of archaeal methanogens in industrial, agricultural and medical settings
WO2025253171A1 (en) 2024-06-04 2025-12-11 Institut Pasteur Characterization of viruses associated with the zoonotic fish-borne oncogenic liver flukes and applications thereof
WO2025257588A1 (en) 2024-06-10 2025-12-18 Affimed Gmbh Cd16a/tumor antigen polyspecific binder for use in the treatment of immune checkpoint inhibitor resistance
WO2026011013A1 (en) 2024-07-02 2026-01-08 Epibiologics, Inc. Binding agents and uses thereof
WO2026033259A1 (en) 2024-08-05 2026-02-12 Lys Therapeutics Antibodies for treating neurological and neurovascular disorders
WO2026036047A1 (en) 2024-08-08 2026-02-12 Altus Enterprises, Inc. Antibody molecules to fixa and fx and uses thereof
WO2026037841A1 (en) 2024-08-12 2026-02-19 ONA Therapeutics S.L. Anti-fgfr4 molecules and uses thereof
WO2026050572A2 (en) 2024-08-29 2026-03-05 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155132A (ja) * 1983-04-08 1985-08-15 ジエネンテツク・インコ−ポレイテツド 組換免疫グロブリン

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60155132A (ja) * 1983-04-08 1985-08-15 ジエネンテツク・インコ−ポレイテツド 組換免疫グロブリン

Cited By (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS61119196A (ja) * 1984-08-27 1986-06-06 ザ　ボ−ド　オブ　トラステイ−ズ　オブ　ザ　リ−ランド　スタンフオ−ド　ジユニア　ユニバ−シテイ Ｄｎａスプライシング及び発現によるキメラ性受容体
JPS61134325A (ja) * 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5846818A (en) * 1985-11-01 1998-12-08 Xoma Corporation Pectate lyase signal sequence
JPS63501765A (ja) * 1985-11-01 1988-07-21 インタ−ナショナル、ジェネティック、エンジニアリング　インコ−ポレ−テッド 抗体遺伝子のモジュ−ル組立体、それにより産生された抗体及び用途
US6204023B1 (en) * 1985-11-01 2001-03-20 Xoma Ltd. Modular assembly of antibody genes, antibodies prepared thereby and use
US5693493A (en) * 1985-11-01 1997-12-02 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5698417A (en) * 1985-11-01 1997-12-16 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5698435A (en) * 1985-11-01 1997-12-16 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
JPS63112995A (ja) * 1986-07-07 1988-05-18 セントコ−・インコ−ポレ−テッド 腫瘍関連抗原に特異的なキメラ齧歯類／ヒト免疫グロブリン
JPS6336786A (ja) * 1986-07-31 1988-02-17 Teijin Ltd 抗体ｌ鎖発現型核酸塩基配列，プラスミド，細胞及びキメラ抗体ｌ鎖
JPS6336796A (ja) * 1986-08-01 1988-02-17 Teijin Ltd マウス−ヒトキメラ抗体、それをコ−ドする発現型キメラｄｎａ配列、プラスミド及び細胞
JPH02501886A (ja) * 1986-10-27 1990-06-28 インターナショナル、ジェネティック、エンジニアリング、インコーポレーテッド ヒト腫瘍抗原に対し特異性を有するキメラ抗体
JPH03504556A (ja) * 1987-05-29 1991-10-09 タノツクス・バイオシステムズ・インコーポレーテツド Ｈｉｖ‐１を中和するモノクローナル抗体
EP0327000A2 (en) 1988-01-30 1989-08-09 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Gene fragments coding for the variable region of an anti-HIV antibody, chimeric anti-HIV antibodies expressed using the same, and process for their preparation
JPH04501503A (ja) * 1988-05-18 1992-03-19 セントカー・インコーポレーテツド 血小板特異的キメラ免疫グロブリン
US5976532A (en) * 1988-05-18 1999-11-02 Centocor, Inc. Method of antithrombotic therapy using anti-GPIIb/IIIa antibodies or fragments thereof, including c7E3
US5877006A (en) * 1988-05-18 1999-03-02 Centocor, Inc. DNAs encoding chimeric immunoglobulin light or heavy chains and fragments thereof having variable regions derived from monoclonal antibody 7E3, and vectors and host cells comprising same
JPH02238883A (ja) * 1988-10-17 1990-09-21 Becton Dickinson & Co 抗―Ｌｅｕ　３ａアミノ酸配列
JPH02231567A (ja) * 1989-01-10 1990-09-13 Boehringer Mannheim Gmbh 血清又は血液中の物質を診断検出する方法
US7544782B2 (en) 1989-08-07 2009-06-09 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7605233B2 (en) 1989-08-07 2009-10-20 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7553641B2 (en) 1989-08-07 2009-06-30 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7528237B2 (en) 1989-08-07 2009-05-05 Arana Therapeutics Limited Tumour necrosis factor binding ligands
US7517963B2 (en) 1989-08-07 2009-04-14 Arana Therapeutics Limited Tumour necrosis factor binding ligands
JPH03254691A (ja) * 1990-03-02 1991-11-13 Japan Found Cancer Res 薬剤耐性癌に対するキメラ抗体およびその製造
JPH0690752A (ja) * 1990-10-17 1994-04-05 Wellcome Found Ltd:The 抗体産生
JPH0584082A (ja) * 1990-10-18 1993-04-06 Boehringer Mannheim Gmbh 抗体遺伝子の可変部をコードするｄｎａフラグメントの単離法、キメラ抗体遺伝子の製法、キメラ抗体の取得法及び医薬の製法
US7223396B2 (en) 1991-03-18 2007-05-29 Centocor, Inc. Methods of treatment of fistulas in Crohn's disease with anti-TNF antibodies
US7204985B2 (en) 1991-03-18 2007-04-17 Centocor, Inc. Methods of treating disseminated intravascular coagulation by multiple administration of anti-TNF antibodies
US6835823B2 (en) 1991-03-18 2004-12-28 New York University Anti-TNF antibodies and peptides of human tumor necrosis factor
US7070775B2 (en) 1991-03-18 2006-07-04 New York University Recombinant A2-specific TNFα specific antibodies
US7101674B2 (en) 1991-03-18 2006-09-05 New York University Anti-idiotypic anti-TNF antibodies and related immunoassay methods
US7128907B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods of treating crohn's disease with anti-TNF antibodies
US7128908B2 (en) 1991-03-18 2006-10-31 Centocor, Inc. Methods for treating systemic lupus erythematosus using anti-TNF antibodies and fragments thereof
US7135179B2 (en) 1991-03-18 2006-11-14 Centocor, Inc. Methods for treating sarcoidosis using anti-TNF antibodies and fragments thereof
US7135178B2 (en) 1991-03-18 2006-11-14 Centocor, Inc. Methods of treating disseminated intravascular coagulation using anti-TNF antibodies
US7138118B2 (en) 1991-03-18 2006-11-21 Centocor, Inc. Methods of treating rheumatoid arthritis with anti-TNF antibodies
US7160543B2 (en) 1991-03-18 2007-01-09 New York University Methods of inhibiting TNF-α in patients with Crohn's disease
US7160542B2 (en) 1991-03-18 2007-01-09 New York University Method of treating psoriasis using human anti-TNF antibodies and fragments
US7160995B2 (en) 1991-03-18 2007-01-09 New York University DNA encoding anti-TNF antibodies and peptides
US7166284B2 (en) 1991-03-18 2007-01-23 New York University Methods of treating joint inflammation with anti-TNF antibodies
US7169388B2 (en) 1991-03-18 2007-01-30 New York University Methods of inhibiting TNFα in patients with cancer
US7169386B1 (en) 1991-03-18 2007-01-30 New York University Methods of treating inflammation associated with viral infection with anti-TNF antibodies
US7179466B2 (en) 1991-03-18 2007-02-20 New York University Methods of treating rheumatoid arthritis by multiple administration of anti-TNF antibodies
US7179893B2 (en) 1991-03-18 2007-02-20 New York University Recombinant anti-TNF-α antibodies
US7192584B2 (en) 1991-03-18 2007-03-20 Centocor, Inc. Methods of treating psoriasis with anti-TNF antibodies
US6790444B2 (en) 1991-03-18 2004-09-14 New York University Medical Center Anti-TNF antibodies and peptides of human necrosis factor
US7214376B2 (en) 1991-03-18 2007-05-08 New York University Methods of inhibiting TNFα in patients with neoplastic disease
US7416729B2 (en) 1991-03-18 2008-08-26 Centocor, Inc. Methods of treating rheumatoid arthritis with anti-TNF antibodies
US7227003B2 (en) 1991-03-18 2007-06-05 New York University Anti-TNF antibody fragments
US7226593B2 (en) 1991-03-18 2007-06-05 Centocor, Inc. Methods of treating cachexia with chimeric anti-TNF antibodies
US7252823B2 (en) 1991-03-18 2007-08-07 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7276239B2 (en) 1991-03-18 2007-10-02 Centocor, Inc. Recombinant A2-specific TNFα-specific antibodies
US7479543B2 (en) 1991-04-25 2009-01-20 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human interleukin-6 receptor
KR100249937B1 (ko) * 1991-04-25 2000-04-01 나가야마 오사무 인간 인터루킨-6 수용체에 대한 재구성 인간 항체
WO1992019759A1 (fr) * 1991-04-25 1992-11-12 Chugai Seiyaku Kabushiki Kaisha Anticorps humains reconstitues diriges contre un recepteur de l'interleukine 6 humaine
KR100266554B1 (ko) * 1993-01-14 2000-09-15 사꼬 미쓰오 재조합항-hiv항체및그의제조방법
WO1994028159A1 (en) * 1993-05-31 1994-12-08 Chugai Seiyaku Kabushiki Kaisha Reconstructed human antibody against human interleukin-6
US6214973B1 (en) 1993-11-19 2001-04-10 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
WO1995014041A1 (en) * 1993-11-19 1995-05-26 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human medulloblastomatous cell
US7563599B2 (en) 1993-11-19 2009-07-21 Chugai Seiyaku Kabushiki Kaisha Reshaped human antibody to human medulloblastoma cells
US7815909B2 (en) 2000-08-07 2010-10-19 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US7820169B2 (en) 2000-08-07 2010-10-26 Centocor, Inc. Anti-TNF antibodies, compositions, methods and uses
US10465003B2 (en) 2016-02-05 2019-11-05 Janssen Biotech, Inc. Anti-TNF antibodies, compositions, methods and use for the treatment or prevention of type 1 diabetes

Also Published As

Publication number Publication date
DE3587360D1 (de) 1993-07-01
EP0171496B1 (en) 1993-05-26
JPH0373280B2 (ja) 1991-11-21
DE171496T1 (de) 1986-07-03
EP0171496A3 (en) 1987-11-25
CA1339201C (en) 1997-08-05
DE3587360T2 (de) 1993-10-14
EP0171496A2 (en) 1986-02-19

Similar Documents

Publication Publication Date Title
EP0171496B1 (en) Process for the production of a chimera monoclonal antibody
KR0164608B1 (ko) 유전자이식 동물로부터 항체 제조방법
JP3186463B2 (ja) マルチチェインポリペプチドまたは蛋白質
US7125689B2 (en) Method for rendering streptokinase less immunogenic to a human
CA1340879C (en) Recombinant dna product and methods
JP2714786B2 (ja) キメラ抗体の産生方法
EP0483961B1 (en) Specific binding agents
EP0419858B1 (en) Dog-mouse heterohybridoma and gene fragment coding for constant region of canine immunoglobulins
EP0332424A2 (en) Chimeric antibodies directed against human carcinoembryonic antigen
JPH08500487A (ja) Ｌ鎖欠落免疫グロブリン
WO1982001461A1 (en) Human hybridomas,precursors and products
JPH03502801A (ja) 単一ドメインリガンド、そのリガンドからなる受容体、その製造方法、ならびにそのリガンドおよび受容体の使用
JPH02500329A (ja) ターゲット化多機能蛋白質
Theofilopoulos et al. Monoclonal IgM rheumatoid factors derived from arthritic MRL/Mp-lpr/lpr mice.
CA1341357C (en) Platelet-specific chimeric immunoglobulin
Russo et al. Sequence defined antibodies improve the detection of cadherin 2 (N-cadherin) during zebrafish development
EP0417486B1 (en) Cat-mouse heterohybridoma and gene fragment coding for constant region of feline immunoglobulin
KR910008637B1 (ko) 심근 미오신 중사슬에 대한 단일클론항체
CA2019323A1 (en) Chimeric mouse-human km10 antibody with specificity to a human tumor cell antigen
JP2544120B2 (ja) 抗ヒト精子不動化単一クロ−ン抗体を産生する細胞株
JPH10501126A (ja) 組換え単鎖Ｆｖ抗体断片、及び組換えＢ型肝炎ウイルス表面抗原の免疫精製のためのその用途
JP2811089B2 (ja) イヌ×マウスヘテロハイブリドーマおよびイヌ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片
EP0491351A2 (en) Chimeric antibodies and their use
JPH05176790A (ja) 脳ミオシンに対するモノクローナル抗体
EP0305619B1 (en) Monoclonal antibody, process for preparation thereof and diagnostic drug containing the same